Use of tumor-infiltrating lymphocyte in disease treatment
By modifying tumor-infiltrating lymphocytes to enhance IL-15 expression and activity, compositions or kits are developed to address the issues of insufficient cell numbers and IL-2 risk in existing treatments, enabling more effective and safer tumor therapy.
Patent Information
- Application Number
- PCT/CN2024/090710
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-05
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-14
AI Technical Summary
Existing methods for treating tumors with tumor-infiltrating lymphocytes require a large number of cells and have weak expansion capabilities, and the use of IL-2 carries the risk of patient intolerance.
By modifying tumor-infiltrating lymphocytes to enhance the expression and activity of cytokines such as IL-15, and combining them with appropriate substances to reduce the number of lymphocytes and maintain their proliferative capacity, compositions or kits are formed for treatment.
It increased the number, activity, and killing ability of tumor-infiltrating lymphocytes, enhanced the therapeutic effect on tumors, and reduced the risk of intolerance in patients.
Smart Images

Figure PCTCN2024090710-FTAPPB-I100001 
Figure PCTCN2024090710-FTAPPB-I100002 
Figure PCTCN2024090710-FTAPPB-I100003
Abstract
Description
Use of tumor-infiltrating lymphocytes in disease treatment Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to the use of tumor-infiltrating lymphocytes (TIL) in the treatment of diseases. Background Art
[0002] Adoptive transfer of autologous tumor-infiltrating lymphocytes (TILs) is an effective treatment for patients with a poor prognosis. However, this approach requires a large number of TILs, and currently, TILs derived from patient tumors have weak expansion capacity and poor cellular function. Furthermore, existing TIL therapies require the administration of the cytokine IL-2, which carries the risk of patient intolerance.
[0003] Therefore, how to provide a robust and reliable tumor-infiltrating lymphocyte that can be used for cell therapy is an urgent problem to be solved.
[0004] Summary of the Invention
[0005] The present invention provides a use of tumor-infiltrating lymphocytes in disease treatment. The tumor-infiltrating lymphocytes obtained using the culture method described in the present invention can demonstrate effectiveness and safety in tumor treatment.
[0006] In one aspect, the present invention provides a TIL population having increased cytokine expression and / or enhanced activity in at least a portion of cells. In another aspect, the present invention provides a composition comprising a TIL population having increased cytokine expression and / or enhanced activity in at least a portion of cells, and a substance that reduces the number of lymphocytes and / or a substance that maintains the proliferation capacity of the TIL population.
[0007] In another aspect, the present invention provides a kit comprising the composition of the present invention.
[0008] In another aspect, the present invention provides a composition and / or a kit for use in preparing a medicament for treating tumors.
[0009] In another aspect, the present invention provides a medicine for treating tumors, comprising a composition and / or a kit.
[0010] In another aspect, the present invention provides a method for treating a tumor, comprising administering the composition and / or kit to a subject in need thereof.
[0011] In another aspect, the present invention provides a composition and / or kit for use in treating tumors.
[0012] In one aspect, the present invention provides a method for treating tumors using a tumor-infiltrating lymphocyte (TIL) population, the method comprising the following steps: (A) increasing the expression and / or enhancing the activity of cytokines in at least a portion of cells in a TIL population derived from tumor tissue to obtain a modified TIL population; and (B) administering a therapeutically effective amount of the modified TIL population to a subject suffering from the tumor.
[0013] Those skilled in the art will readily appreciate other aspects and advantages of the present invention from the detailed description below. The detailed description below only shows and describes exemplary embodiments of the present invention. As will be appreciated by those skilled in the art, the disclosure of the present invention enables those skilled in the art to modify the disclosed embodiments without departing from the spirit and scope of the invention to which the present invention relates. Accordingly, the descriptions in the drawings and specification of the present invention are intended to be exemplary only and not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 shows the CD4 TIL cells from donor A in each group. + IL-15 transduction efficiency of cells.
[0015] Figure 2 shows the CD8 TIL cells from donor A in each group. + IL-15 transduction efficiency of cells.
[0016] FIG3 shows the normalized expansion rate of TIL cells in each group for TIL cells derived from donor B.
[0017] FIG4 shows the viability of TIL cells in each group for TIL cells derived from donor B.
[0018] FIG5 shows the proliferation capacity of TIL cells from donor C in each group.
[0019] Figures 6, 7 and 8 respectively show the secretion of cytokines IL-2, IFN-γ and IL-10 by TIL cells from donor D in each group after CD3 antibody stimulation.
[0020] Figures 9 and 10 respectively show the secretion of cytokines TNF-α and IL-10 by TIL cells from donor E in each group after transACT stimulation.
[0021] FIG11 and FIG12 respectively show the secretion of cytokines IFN-γ and IL-2 by TIL cells from donor F in each group.
[0022] Figures 13 and 14 respectively show the secretion of cytokines IFN-γ and IL-6 by TIL cells in each group when TIL cells from donor G were cultured without IL-2.
[0023] FIG15 shows the killing ability test results of TIL cells derived from donor H, co-cultured with tumor cells at an effector-target ratio of 0.3:1.
[0024] FIG16 shows the results of the killing ability test of TIL cells derived from donor H when co-cultured with tumor cells at an effector-target ratio of 1:1.
[0025] FIG17 shows the results of IL-2 secretion by TIL cells derived from donor H co-cultured with tumor cells at an effector-target ratio of 0.3:1 or 1:1.
[0026] FIG18 shows the results of IFN-γ secretion by TIL cells derived from donor H co-cultured with tumor cells at an effector-target ratio of 0.3:1 or 1:1.
[0027] FIG19 shows the CD8 TIL cells from donor 1 on day 8 after transduction. + Diversity of T cell TCR Vβ clones.
[0028] FIG20 shows the CD8 TIL cells from donor 1 on day 26 after transduction. + Diversity of T cell TCR Vβ clones.
[0029] FIG21 shows the CD4 TIL cells from donor 1 on day 8 after transduction. + Diversity of T cell TCR Vβ clones.
[0030] Figure 22 shows the CD4 TIL cells from donor 1 on day 26 after transduction. + Diversity of T cell TCR Vβ clones.
[0031] Figure 23, Figure 24, Figure 25, Figure 26 and Figure 27 respectively show the number of T cells in various tissues on the 6th day and the 21st day after the injection of TIL cells.
[0032] FIG28 shows the therapeutic effect of TIL cells genetically modified to express IL-15 according to the present invention. DETAILED DESCRIPTION
[0033] The following describes the embodiments of the present invention through specific embodiments. People skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0034] Definition of terms
[0035] In the present invention, the term "interleukin" or "interleukin" generally refers to a cytokine. For example, interleukins can activate and regulate immune cells, mediate T cell and B cell activation, proliferation, or differentiation, and can play an important role in inflammatory responses. In the present invention, interleukins can include unprocessed interleukins, any form of processed interleukins, interleukin variants, or substances containing functionally active fragments of interleukins.
[0036] In this invention, the terms "comprising," "containing," and "including" are open-ended expressions with the same meaning and can be used interchangeably. "Comprising A" means that in addition to A, other substances, such as B and C, are also included. Furthermore, this term also includes the closed-ended expression "consisting of." The latter is a special form of the former.
[0037] In the present invention, the term "interleukin-15" or "IL-15" generally refers to a type of cytokine. For example, IL-15 can be found in GenBank Accession No. P40933. The IL-15 protein of the present invention also encompasses functionally active fragments thereof, and is not limited to substances comprising functionally active fragments of IL-15 produced after processing and / or modification in cells. For example, the IL-15 of the present invention may comprise functionally active fragments of IL-15 as well as any other domains.
[0038] In the present invention, the term "IL-15 domain" generally refers to a domain comprising a functionally active fragment of IL-15. For example, the IL-15 domain of the present invention may encompass functionally active fragments of IL-15 and variants thereof. For example, a substance comprising an IL-15 domain of the present invention may possess the function of IL-15 in regulating immune cells.
[0039] In the present invention, the term "IL-15Ra extracellular domain" generally refers to the extracellular portion of an IL-15 receptor. For example, the IL-15 receptor can be IL-15Ra (also known as IL-15Rα). For example, IL-15Ra can be found in GenBank Accession No. Q13261. For example, the IL-15Ra extracellular domain can include a functionally active fragment of IL-15Ra, and is not limited to substances containing functionally active fragments of IL-15Ra produced after processing and / or modification in cells. For example, the IL-15Ra extracellular domain of the present invention can have the function of binding to IL-15 or a fragment thereof.
[0040] In the present invention, the term "transmembrane domain" generally refers to a portion that spans the cell membrane. For example, the portion located in the cell membrane can be, for example, the transmembrane region of various polypeptides. Fragments of a transmembrane domain can include functionally active fragments, truncations, and / or mutant variants of a wild-type transmembrane domain. For example, a transmembrane domain of the present invention can have the function of binding a substance containing the transmembrane domain to the cell membrane.
[0041] In the present invention, the term "intracellular domain" generally refers to the intracellular portion located on the inner side of the cell membrane. For example, the intracellular domain of the present invention may include functionally active fragments, truncations and / or mutant variants of the wild-type intracellular domain. For example, the intracellular domain of the present invention may not have any intracellular signaling function or may have any intracellular signaling function. For example, the intracellular domain of the present invention may have the effect of enabling, maintaining and / or promoting overall structural stability.
[0042] In the present invention, the term "signal peptide domain" generally refers to a short peptide chain that guides the transfer of newly synthesized proteins to the secretory pathway. For example, the signal peptide domain of the present invention may comprise a functionally active fragment, truncation, and / or mutant variant of a wild-type signal peptide domain. For example, the signal peptide domain of the present invention may have the function of guiding the transmembrane transfer of a substance comprising the signal peptide domain. For example, the signal peptide domain of the present invention may bind to a signal peptide-binding substance, thereby causing all or part of the substance comprising the signal peptide domain to be transferred to the extracellular region outside the cell membrane.
[0043] In the present invention, the term "membrane anchored" generally refers to a substance that can exist in a form located on the cell membrane. For example, a membrane-anchored substance may mean that the substance can be distributed on the cell membrane. For example, a membrane-anchored substance may be partially or completely embedded in the cell membrane or on both the inside and outside sides. For example, a membrane-anchored substance may penetrate the cell membrane, a membrane-anchored substance may be combined with components of the cell membrane through ionic bonds, hydrogen bonds or other interactions, and a membrane-anchored substance may also interact with other substances and indirectly bind to the membrane. For example, a substance may be detected by flow cytometry or other methods of detecting cells to determine whether it is a membrane-anchored substance. For example, a membrane-anchored substance may exist in a membrane-anchored form for a period of time and / or in a certain proportion.
[0044] As used herein, the term "viral vector" generally refers to a virus that can be used to deliver nucleic acids. For example, a viral vector can be used to infect a target cell, delivering the target nucleic acid into the target cell, so that the target cell can express the gene encoded by the target nucleic acid. For example, the viral vector can be a lentiviral vector.
[0045] In the present invention, the term "retroviral vector" generally refers to a vector derived from at least a portion of a retroviral genome. For example, a retroviral vector can convert RNA into cDNA under the action of a reverse transcriptase, and after infecting a target cell, one or more transgenes contained in a heterologous nucleic acid sequence can be expressed in the target cell. For example, retroviral vectors can be used in the clinic, and can also be used, including but not limited to lentiviral vectors. In the present invention, the term "lentiviral vector" generally refers to a vector derived from at least a portion of a lentiviral genome. For example, a lentiviral envelope protein can include a gene encoding an env protein or a portion thereof. For example, a host cell can be transfected with a transfer vector and one or more packaging vectors to produce a virus, which can be used to infect a target cell to express one or more transgenes contained in a heterologous nucleic acid sequence in the target cell.
[0046] In the present invention, the term "introduction" generally refers to the incorporation of a nucleic acid into a eukaryotic or prokaryotic cell. For example, introduction can refer to the incorporation of a heterologous or isolated nucleic acid into a eukaryotic or prokaryotic cell, wherein the nucleic acid can be incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid or mitochondrial DNA), converted into an autonomous replicon or transiently expressed (e.g., transfected mRNA). For example, introduction can be achieved by methods such as "infection", "transfection", "transformation" and "transduction". For example, various methods can be used to introduce nucleic acids into prokaryotic cells, including transfection by electroporation, calcium phosphate precipitation, lipid mediation, and viral vector transduction.
[0047] In the present invention, the term "cyclophosphamide" generally refers to a cell-treating agent. For example, a mustard gas alkylating agent that can convert alkyl (C n H 2n+1 ) is added to DNA. For example, cyclophosphamide can refer to the molecular formula C7H 15 Cl2N2O2P·H2O, chemical name 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazophosphorus 2-oxide monohydrate. For example, the CAS registration number for cyclophosphamide may be a formulation of 50-18-0. Cyclophosphamide is commercially available.
[0048] In the present invention, the term "fludarabine" generally refers to a preparation for treating cells. For example, a fluorinated nucleotide analog. For example, fludarabine can refer to a molecule with the formula C 10 H 12 FN5O4, preparation with CAS registration number 21679-14-1.
[0049] In the present invention, the term "expression" generally refers to the transcription and / or translation process of a gene encoding a target polypeptide in a cell. The transcription level of a gene encoding a target polypeptide in a host cell can be determined by measuring the amount of the corresponding mRNA present in the cell. For example, mRNA transcribed from a gene encoding a target polypeptide can be quantitatively measured by PCR or by Northern hybridization. The translation level of a gene encoding a target polypeptide can be measured by a variety of methods, such as by ELISA, by a polypeptide biological activity test, or by Western blotting or radioimmunoassay.
[0050] In the present invention, the term "stage" in "a stage of in vitro expansion", "a single in vitro expansion stage", or "a first stage of in vitro expansion" generally refers to a stage of expansion that TIL undergoes in vitro. In one embodiment, each stage can be divided by a change in the number of TIL cells. In one embodiment, when the number of TIL cells increases by at least about 1 times, the TIL cells can be considered to have entered the next stage of in vitro expansion. In some embodiments, when the number of TIL cells increases by at least about 1 times to about 50 times, for example, at least about 1 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 11 times, at least about 12 times, at least about 13 times, at least about 14 times, at least about 15 times, at least about 20 times, at least about 30 times, at least about 40 times, or at least about 50 times, the TIL cells can be considered to have entered the next stage of in vitro expansion. In one embodiment, each stage can also be divided by the conditions of TIL cell culture. In one embodiment, when T cell co-stimulatory molecules and / or T cell growth factors are added or supplemented to the cell culture medium, the TIL cells can be considered to have entered the next stage of in vitro expansion. In one embodiment, when the TIL cells are centrifuged and / or washed, the TIL cells can be considered to have entered the next stage of in vitro expansion. In one embodiment, each stage can also be divided by the number of days of TIL cell culture. In one embodiment, after the TIL cells have been cultured in vitro for about 1 day to about 100 days, for example, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 30 days, about 40 days, about 50 days or about 100 days, the TIL cells can be considered to have entered the next stage of in vitro expansion.
[0051] In the present invention, the term "first stage in vitro expansion" generally refers to the stage of expansion using T cell growth factors after obtaining primary TILs from tissue. In one embodiment, the tissue can be tumor tissue. In one embodiment, the expansion can be in vivo expansion of autologous or allogeneic tissue, or it can be in vitro expansion. This first stage of expansion can also be referred to as the preREP (pre-rapid expansion) stage.
[0052] In the present invention, the term "second stage of in vitro expansion" generally refers to the stage in which the tissue removed from the subject is expanded and then expanded again. In one embodiment, the number of TIL cells expanded in the second stage is increased compared to the TIL expanded in the first stage, for example, it can be increased by at least about 10 times to about 90 times, for example, at least about 10 times (or at least about 20, 30, 40, 50, 60, 70, 80 or 90 times), or in one embodiment, the number of cells can be increased by at least about 100 times. In one embodiment, the culture conditions for the second stage expansion can be different from those for the first stage expansion, for example, the culture substances added can be different. The second stage expansion can also be referred to as the REP (rapid expansion) stage.
[0053] In the present invention, the term "in vivo" generally refers to events that occur within the body of a subject.
[0054] In the present invention, the term "in vitro" generally refers to events that occur outside the body of a subject.
[0055] In the present invention, the term "ex vivo" generally refers to an event involving treatment or surgery on cells, tissues and / or organs that have been removed from the subject's body. In one embodiment, the cells, tissues and / or organs can be returned to the subject's body through surgery or treatment.
[0056] In the present invention, the term "secretion" generally refers to the transfer of expressed polypeptides or proteins by cells to the extracellular environment.
[0057] In the present invention, the term "secretion capacity" generally refers to the ability of a cell to express a polypeptide or protein and transfer the polypeptide or protein to the extracellular environment.
[0058] In the present invention, the term "irradiation" generally refers to the treatment of a substance by radiation. For example, in one embodiment, irradiation may refer to irradiating a substance by X-rays, α-rays, β-rays, or γ-rays.
[0059] In the present invention, the term "engineered cell" generally refers to a cell that has been genetically modified by the addition of additional genetic material in the form of DNA or RNA to the total genetic material of the cell. In one embodiment, the engineered cell can be genetically modified to express TILs of T cell costimulatory molecules and / or T cell growth factors according to the present invention.
[0060] In the present invention, the term "co-culture" generally refers to culturing two or more different populations of cells with a certain degree of contact between them. The "contact" of the two or more different populations of cells can be direct contact, i.e., direct physical contact between cells of one population and cells of another population, in one embodiment. Alternatively, the contact can be indirect contact mediated by a shared culture medium. The shared culture medium can contain metabolites produced and released by at least one population of co-cultured cells and be used to culture the cells of the other population.
[0061] In the present invention, the term "contact" generally refers to the contact of two or more different types of substances in any order, in any manner, and for any duration. In one embodiment, direct contact can be used, for example, by adding a feeder cell, a T cell co-stimulatory molecule, and / or a T cell growth factor to the culture medium of TIL cells. In another embodiment, indirect contact can be used, for example, by using metabolites produced and released by feeder cells to culture TIL cells.
[0062] In the present invention, the term "mixture" generally refers to a combination of two or more different substances.
[0063] In the present invention, the terms "contacting simultaneously," "contacting together," "contacting simultaneously with," "concurrently," and "concurrently" generally refer to administering two or more substances to a subject such that the substances are simultaneously present in the subject and / or the environment in which the subject is cultured. Concurrent contact can include administering different compositions simultaneously, administering different compositions at different times, or administering a composition in which two or more active pharmaceutical ingredients are present.
[0064] In the present invention, the term "expanded" generally refers to an increase in the number of cells by several times over a period of time. In one embodiment, the number of cells can increase by at least about 3 times to about 9 times, such as at least about 3 times (or 4, 5, 6, 7, 8 or 9 times), in one embodiment, the number of cells can increase by at least about 10 times to about 90 times, such as at least about 10 times (or 20, 30, 40, 50, 60, 70, 80 or 90 times), or in one embodiment, the number of cells can increase by at least about 100 times. In the present invention, the term "expanded" generally refers to the cells undergoing one or more of the above-mentioned amplifications.
[0065] In the present invention, the term "polymer" generally refers to a molecule consisting of separate chemical parts connected together, which parts may be the same or different. In one embodiment, the term "polymer" can refer to separate chemical parts connected end-to-end to form a linear molecule, as well as separate chemical parts connected together in the form of a branched (such as a "multi-arm" or "star") structure. In one embodiment, a polymer can include, for example, a hydrogel, polyethylene glycol, or a poloxamer. A poloxamer is a nonionic triblock copolymer having a polyoxypropylene (poly(propylene oxide)) central hydrophobic chain flanked by two polyoxyethylene (poly(ethylene oxide)) hydrophilic chains. The substances included in the present invention can be formulated with any polymer described herein or known in the art, or administered together with them.
[0066] In the present invention, the term "antibody" generally refers to an immunoglobulin that is reactive to a specified protein or peptide or its fragment. Such antibodies include, but are not limited to, human antibodies, primatized antibodies, chimeric antibodies, monoclonal antibodies, monospecific antibodies, polyclonal antibodies, multispecific antibodies, non-specific antibodies, bispecific antibodies, multispecific antibodies, humanized antibodies, synthetic antibodies, recombinant antibodies, hybrid antibodies, mutant antibodies, grafted conjugated antibodies (i.e., antibodies that are coupled or fused to other proteins, radiolabeled substances, cytotoxins), and antibodies generated in vitro. Antibodies can be from any class of antibodies, including but not limited to IgG, IgA, IgM, IgD, and IgE, and from any subclass (e.g., IgG1, IgG2, IgG3, and IgG4). Antibodies can have a heavy chain constant region selected from, for example, IgG1, IgG2, IgG3, or IgG4. Antibodies can also have a light chain selected from, for example, kappa (κ) or lambda (λ). The antibodies may be derived from any species, including but not limited to mice, humans, camels, llamas, fish, sharks, goats, rabbits, chickens, and cattle. The constant region of an antibody may be altered, such as by mutation, to modify the properties of the antibody (e.g., to increase or decrease one or more of the following: Fc receptor binding, antibody glycosylation, the number of cysteine residues, effector cell function, or complement function). Typically, an antibody specifically binds to a predetermined antigen, such as an antigen associated with a disorder, such as an inflammatory, immune, autoimmune, neurodegenerative, metabolic, and / or malignant disorder.
[0067] In the present invention, the term "anti-CD3 antibody" generally refers to an antibody or variant thereof targeting CD3, such as a monoclonal antibody, including human, humanized, chimeric, or murine antibodies, that is directed against the CD3 receptor in the T cell antigen receptor of mature T cells. Anti-CD3 antibodies may include OKT-3. Anti-CD3 antibodies may also include other anti-CD3 antibodies, including, for example, in one embodiment, otelixizumab, teplizumab, and visilizumab.
[0068] In the present invention, the term "IL-2" or "IL2" generally refers to the T cell growth factor known as interleukin 2 and includes all forms of IL-2, including, in one embodiment, human and mammalian forms, conservative amino acid substitutions, glycoform modifications or variants, or active fragments thereof. The GeneID encoding the IL2 gene may be 3558.
[0069] In the present invention, the term "antigen presenting cell", "antigen presenting cell", or "APC" generally refers to an immune system cell, such as an auxiliary cell (e.g., B cell, dendritic cell, etc.), that displays an exogenous antigen in complex with a major histocompatibility complex (MHC) on its surface. T cells can recognize these complexes using their T cell receptors (TCR). APCs can process antigens and present them to T cells. In one embodiment, antigen presenting cells can include those selected from the group consisting of peripheral mononuclear cells, dendritic cells, and artificial antigen presenting cells.
[0070] In the present invention, the term "TIL characteristics" generally refers to the characteristics of TIL cells obtained through the culture method of the present invention. Changes in TIL characteristics may include: increased TIL cell number, increased proportion of viable cells, increased survival ability, improved T cell subset ratio, improved cytokine secretion ability, improved tumor cell killing ability, increased T cell receptor (TCR) clonal diversity and increased number of TIL cells in tissues and / or tumors, or any combination thereof. The changes of the present invention may be an increase or decrease. In the present invention, the term "amplification effect" generally refers to the effect that occurs after cells are amplified. Changes in the amplification effect may include changes in the number and / or proportion of cells, changes in secretion ability, changes in killing ability or changes in expression ability, or any combination thereof. The changes may be an increase or decrease.
[0071] In the present invention, the term "expanded" generally refers to cells cultured to produce a change in the number of cells. Expanded cells may also produce a change in the number and / or ratio of cells, a change in secretory capacity, a change in cytotoxicity, or a change in expression capacity, or any combination thereof. The change may be an increase or decrease.
[0072] In the present invention, the term "nanoparticle" generally refers to a microscopic particle having at least one dimension less than 100 nm. Typically, nanoparticles have a diameter in the range of 50 nm to 500 nm (i.e., 0.05 μm to 0.5 μm); are structurally stable in physiological environments; and can accommodate smaller molecules (such as drugs or other bioactive agents), which can then be delivered to the desired site.
[0073] In the present invention, the term "artificial antigen presenting cell" generally refers to an artificially constructed immune system cell for displaying an exogenous antigen complexed with a major histocompatibility complex (MHC). In one embodiment, an isolated artificial antigen presenting cell (aAPC) may be included, which may include cells expressing HLA-A / B / C (the gene encoding it may be 3105, 3106, or 3107), CD64 (the gene encoding it may be 2209), CD80 (the gene encoding it may be 941), ICOS-L (the gene encoding it may be 23308), and CD58 (the gene encoding it may be 965), and may be modified to express one or more costimulatory molecules.
[0074] In the present invention, the term "fusion protein" generally refers to a polypeptide or protein containing the amino acid sequence of a first polypeptide or protein or a fragment, analog or derivative thereof and the amino acid sequence of a heterologous polypeptide or protein (i.e., a second polypeptide or protein or a fragment, analog or derivative thereof that is different from the first polypeptide or protein or a fragment, analog or derivative thereof, or that is not generally a part of the first polypeptide or protein or a fragment, analog or derivative thereof). In some cases, a fusion protein may comprise a prophylactic or therapeutic drug fused to a heterologous protein, polypeptide or peptide. The heterologous protein, polypeptide or peptide may or may not be a different type of prophylactic or therapeutic drug. For example, two different proteins, polypeptides or peptides having immunomodulatory activity can be fused together to form a fusion protein. In some cases, the fusion protein can retain or increase the activity compared to the activity of the original polypeptide or protein before fusion of the heterologous protein, polypeptide or peptide.
[0075] In the present invention, the term "killing ability" generally refers to killing target cells by contacting the cells with an effective amount of a substance. In one embodiment, the substance can be a TIL cell. The killing can include killing cells by itself or by promoting CDC, apoptosis, ADCC, and / or phagocytosis of other cells or substances, or by a combination of two or more of these mechanisms.
[0076] As used herein, the term "administer" generally refers to delivering a substance to a subject in need thereof by any route known in the art. Pharmaceutical carriers and formulations or compositions are also well known in the art. Routes of administration may include intravenous, intramuscular, intradermal, subcutaneous, transdermal, mucosal, intratumoral, and / or mucosal.
[0077] In the present invention, the term "kit" generally refers to two or more components packaged together in a container, receptacle or other container, one of which corresponds to a substance of the present invention, for example, comprising TIL cells of the present invention.
[0078] In the present invention, the term "subject" generally refers to a cell or an animal, which can be a mammal, such as a human, a non-human primate (ape, gibbon, gorilla, chimpanzee, orangutan, macaque), livestock (dogs and cats), farm animals (poultry such as chickens and ducks, horses, cattle, goats, sheep, pigs) and experimental animals (mice, rats, rabbits, guinea pigs). Human subjects include fetuses, newborns, infants, adolescents and adult subjects. Subjects include animal disease models, such as tumor animal models, and other animal models known to those skilled in the art.
[0079] In the present invention, the term "feeder cell" generally refers to a cultured cell that grows in vitro and secretes at least one factor into a culture medium and can be used to support the growth of another target cell. In one embodiment, the feeder cell may include an antigen presenting cell.
[0080] In the present invention, the term "specific binding" generally refers to an antibody that recognizes a specific antigen but does not substantially recognize or bind to other molecules in the sample. For example, if an antibody can specifically bind to a specific antigen from one species, the antibody may also specifically bind to the antigen or homologous antigen from one or more other species. This interspecies reactivity itself may not change the classification of the antibody as specific. In some cases, an antibody that specifically binds to an antigen may also bind to a different epitope form of the antigen.
[0081] In the present invention, the term "complete culture process" generally refers to the complete process starting from isolating cells from tumor tissue isolated from a patient's body, undergoing one or more amplifications, and finally obtaining cells that can be administered to a subject.
[0082] As used herein, the term "cell culture medium" generally refers to a nutrient solution in which cells, such as mammalian cells, are grown. The preparation of cell culture media is well known in the art. Typically, a cell culture medium comprises a buffer, salts, carbohydrates, amino acids, vitamins, and essential trace elements. A cell culture medium may or may not contain serum, peptone, and / or protein. A cell culture medium may be supplemented with additional components or increased concentrations of components, such as amino acids, salts, sugars, vitamins, hormones, growth factors, buffers, antibiotics, lipids, trace elements, etc., depending on the requirements of the cells to be cultured and / or the desired cell culture parameters.
[0083] In the present invention, the term "pharmaceutical preparation" generally refers to a preparation that allows the biological activity of the active ingredient to be effective and does not contain additional components that are unacceptably toxic to the subject to whom the preparation will be administered. Such preparations are sterile. "Pharmaceutically acceptable" excipients (carriers, additives) are those that can be reasonably administered to a subject mammal to provide an effective dose of the active ingredient used.
[0084] In the present invention, the term "tumor infiltrating lymphocytes" or "TIL" generally refers to a population of cells originally obtained as leukocytes that have left the bloodstream of a subject and migrated into a tumor. TIL can include, but is not limited to, CD8 + Cytotoxic T cells (lymphocytes), Th1 and Th17CD4 + T cells, natural killer cells, dendritic cells and M1 macrophages. TIL can include primary TIL and secondary TIL. "Primary TIL" can be those TIL cells obtained from a subject's tissue sample, and "secondary TIL" can be any TIL cell population that has been expanded or amplified in the present invention. In some embodiments, the tumor infiltrating lymphocytes may not be isolated and purified, or may be infiltrating with tumor cells. In one embodiment, the TIL of the present invention may refer to a TIL cell population.
[0085] In the present invention, "CD4 + Cells" generally refer to CD4-positive cells, such as T cells. The term "CD4 + "CD4 positive cells" are synonymous and can be used interchangeably. These cells can be identified by methods known in the art, such as staining the cells with fluorescently labeled antibodies against CD4 and using fluorescence activated cell sorting. For example, the prior art can demonstrate that CD4 + Increasing the cell ratio can increase the ability of the cell population to secrete IFN-γ and / or TNF, and can enhance the effect of the T cell population in promoting tumor suppression. For example, see Tay, RE, Richardson, EK et al. (2020). Cancer Gene Therapy, 1-13. However, there is a lack of a method to increase CD4 + The present invention can provide a method for affecting the CD4 + Cell ratio method.
[0086] In the present invention, "CD8 + Cells” generally refer to CD8-positive cells, such as T cells. The term “CD8 +"CD8 positive cells" and "CD8 positive cells" are synonymous and can be used interchangeably. These cells can be identified by methods known in the art, such as by staining the cells with fluorescently labeled antibodies against CD8 and using fluorescence activated cell sorting.
[0087] In the present invention, the term "central memory T cells" generally refers to T cells with long-term memory and capable of accepting antigen restimulation. Central memory T cells may have CD45RA - CCR7 + The phenotype, for example, can be expressed by CD45RA - and CCR7 + To identify central memory T cells. For example, central memory T cells may have CD45RO + CD62L + The phenotype can be, for example, CD45RO + and CD62L + To identify central memory T cells. Central memory T cells can have stronger anti-tumor growth ability than ordinary T cells.
[0088] In the present invention, the term "regulatory T cells" generally refers to a type of T cell subpopulation that controls autoimmune reactivity in the body. Regulatory T cells may have CD4 + CD25 + Foxp3 + The phenotype can be, for example, CD4 + 、CD25 + and Foxp3 + To identify regulatory T cells, which can suppress the anti-tumor growth ability of T cells.
[0089] In the present invention, the term "activated T cells" generally refers to T cells that have been activated to have the ability to resist tumor growth. Activated T cells may have PD1 + , LAG3 + or CD28 + The phenotype, for example, can be PD1 + , LAG3 + or CD28 + To identify activated T cells. Activated T cells can have the ability to fight tumor growth.
[0090] In the present invention, the term "tumor-specific T cells" generally refers to T cells that can specifically resist tumor growth. Tumor-specific T cells may have CD103 + CD39 + The phenotype can be, for example, CD103 + and CD39 +To identify tumor-specific T cells. Tumor-specific T cells can have more specific anti-tumor growth capabilities than ordinary T cells.
[0091] In the present invention, the term "stem cell-like T cells" generally refers to a type of T cells that can have the potential for self-proliferation and / or differentiation. Stem cell-like T cells can have TCF1 + The phenotype, for example, can be caused by TCF1 + To identify stem cell-like T cells. Tumor-specific T cells may have stronger and / or longer-lasting anti-tumor growth capabilities than conventional T cells.
[0092] In the present invention, the term "NK cell," also known as "natural killer cell," generally refers to a cell with large granules in its cytoplasm. NK cells develop from bone marrow lymphoid stem cells and can differentiate and develop in the bone marrow or thymic microenvironment. In the present invention, the proportion of NK cells in TIL cells can be altered using the methods of the present invention.
[0093] In the present invention, the term "tumor fragments" generally refers to tumor fragments formed by crushing tumor tissue after it is removed from a subject.
[0094] In the present invention, the term "composition" or "pharmaceutical composition" generally refers to a mixture of at least one cell and optionally more than one other pharmaceutically acceptable chemical components such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners and / or excipients.
[0095] In the present invention, the term "pharmaceutically acceptable carrier" generally refers to one or more non-toxic materials that do not interfere with the effectiveness of the biological activity of the active ingredient. Such preparations can conventionally contain salts, buffers, preservatives, compatible carriers and optionally other therapeutic agents. Such pharmaceutically acceptable preparations can also contain compatible solid or liquid fillers, diluents or encapsulating materials suitable for administration to people. Other envisioned carriers, excipients, and / or additives that can be used in the preparations described herein may include: for example, flavorings, antimicrobials, sweeteners, antioxidants, antistatic agents, lipids, protein excipients (such as serum albumin, gelatin, casein), salt-forming counterions (such as sodium) and the like. These and other pharmaceutical carriers, excipients, and / or additives suitable for use in the preparations described herein are known in the art.
[0096] In the present invention, the term "T cell co-stimulatory molecule" generally refers to a ligand that binds to a corresponding binding receptor on a T cell and mediates a T cell co-stimulatory response. Co-stimulatory molecules can be cell surface molecules other than antigen receptors or their ligands required for an effective immune response. Co-stimulatory molecules can include but are not limited to MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signal lymphocyte activation molecules (SLAM proteins), NK cell activation receptors, BTLA (the gene GeneID encoding it can be 151888), Toll ligand receptor, OX40 (the gene GeneID encoding it can be 7293), CD2 (the gene GeneID encoding it can be 914), CD7 (the gene GeneID encoding it can be 924), CD27 (the gene GeneID encoding it can be 939), CD28 (the gene GeneID encoding it can be 9 40), CD30 (the gene encoding it may be 943), CD40 (the gene encoding it may be 958), CDS, ICAM-1 (the gene encoding it may be 3383), LFA-1 (CD11a / CD18) (the gene encoding it may be 3689), 4-1BB (CD137) (the gene encoding it may be 3604), B7-H3 (the gene encoding it may be 80381), ICOS (CD278) (the gene encoding it may be 29851 ), GITR (the gene encoding it may be 8784), BAFFR (the gene encoding it may be 115650), LIGHT (the gene encoding it may be 8740), HVEM (LIGHTR) (the gene encoding it may be 8764), KIRDS2 (the gene encoding it may be 100132285), SLAMF7 (the gene encoding it may be 57823), NKp80 (KLRF1) (the gene encoding it may be 51348), NKp4 4 (the gene encoding it may be 9436), NKp30 (the gene encoding it may be 259197), NKp46 (the gene encoding it may be 9437), CD19 (the gene encoding it may be 930), CD4 (the gene encoding it may be 920), CD8α (the gene encoding it may be 925), CD8β (the gene encoding it may be 926), IL-2Rβ, IL-2Rγ, IL7Rα (the gene encoding it may be 3575),ITGA4 (the gene encoding it may be 3676), VLA1 (the gene encoding it may be 3672), CD49a (the gene encoding it may be 3672), IA4 (the gene encoding it may be 3732), CD49D (the gene encoding it may be 3676), ITGA6 (the gene encoding it may be 3655), VLA-6 (the gene encoding it may be 3655), CD49f (the gene encoding it may be 3655), ITGAD (the gene encoding it may be 3681), CD11 d (the gene encoding it may be 3681), ITGAE (the gene encoding it may be 3682), CD103 (the gene encoding it may be 3682), ITGAL (the gene encoding it may be 3683), CD11a (the gene encoding it may be 3683), LFA-1 (the gene encoding it may be 3683), ITGAM (the gene encoding it may be 3684), CD11b (the gene encoding it may be 3684), ITGAX (the gene encoding it may be 3687), CD11c ( The gene encoding it may be 3687), ITGB1 (the gene encoding it may be 3688), CD29 (the gene encoding it may be 3688), ITGB2 (the gene encoding it may be 3689), CD18 (the gene encoding it may be 3689), LFA-1 (the gene encoding it may be 3689), ITGB7 (the gene encoding it may be 3695), NKG2D (the gene encoding it may be 22914), NKG2C (the gene encoding it may be 3822), TNFR2 (the gene encoding it may be 3823), and TNFR3 (the gene encoding it may be 3824). The gene GeneID may be 7133), TRANCE / RANKL (the gene encoding it may be 8600), DNAM1 (CD226) (the gene encoding it may be 10666), SLAMF4 (CD244, 2B4) (the gene encoding it may be 51744), CD84 (the gene encoding it may be 8832), CD96 (Tactile) (the gene encoding it may be 10225), CEACAM1 (the gene encoding it may be 634), CRTAM (the gene encoding it may be 56253),Ly9 (CD229) (the gene encoding it may be 4063 in GeneID), CD160 (BY55) (the gene encoding it may be 11126 in GeneID), PSGL1 (the gene encoding it may be 6404 in GeneID), CD100 (SEMA4D) (the gene encoding it may be 10507 in GeneID), CD69 (the gene encoding it may be 969 in GeneID), SLAMF6 (NTB-A, Ly108) (the gene encoding it may be 114836 in GeneID), SLAM (SLAMF1, CD150, IPO-3) (the gene encoding it may be 6504 in GeneID), BLAME (SLAMF8) (the gene encoding it may be 114836 in GeneID), D can be 56833), SELPLG (CD162) (the gene encoding it can be 6404), LTBR (the gene encoding it can be 4055), LAT (the gene encoding it can be 27040), GADS (the gene encoding it can be 9402), SLP-76 (the gene encoding it can be 3937), PAG / Cbp (the gene encoding it can be 55824), CD19a, and a ligand that specifically binds to CD3, a ligand that specifically binds to CD28, a ligand that specifically binds to HVEM, a ligand that specifically binds to CD40L, a ligand that specifically binds to OX40, and a ligand that specifically binds to 4-1BB. The co-stimulatory intracellular signaling domain refers to the intracellular portion of a co-stimulatory molecule. The intracellular signaling domain can comprise the entire intracellular portion of the molecule from which it is derived or the entire native intracellular signaling domain or a functional fragment thereof. 、
[0097] In the present invention, the term "T cell growth factor" generally refers to a biologically active polypeptide or small molecule compound that causes cell proliferation. In one embodiment, the T cell growth factor can be selected from one or more of the following groups: IL-2 (the gene encoding the factor may be 3558), IL-4 (the gene encoding the factor may be 3565), IL-7 (the gene encoding the factor may be 3574), IL-10 (the gene encoding the factor may be 3586), IL-12 (the gene encoding the factor may be 3592 or 3593), IL-15 (the gene encoding the factor may be 3600), and interferon-gamma (the gene encoding the factor may be 3458).
[0098] In the present invention, the term "substantially simultaneously" generally refers to a period of time during which the TIL can be in contact with two or more substances simultaneously, but is not limited to always being in contact with two or more substances simultaneously during the entire contact process. For example, substantially simultaneously can mean that the TIL can be in contact with at least 10% to 95%, such as at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, or 95% of each of the two or more substances simultaneously during a period of time.
[0099] In the present invention, the term "tumor" generally refers to any new pathological tissue proliferation. The tumors of the present invention may be benign or malignant. The tumors of the present invention may be solid or hematologic. The term "tumor" may be selected from one or more of the following groups: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and kidney cancer.
[0100] In the present invention, the term "tumor tissue" generally refers to a sample from a tumor in a subject, including any solid tumor and / or any tissue that is not a solid tumor in a subject.
[0101] In the present invention, the terms "object" and "subject" are synonymous and can be used interchangeably.
[0102] In the present invention, the terms "about" and "approximately" generally refer to a statistically significant numerical range. Such a range can be within an order of magnitude of a given value or range, can be included within 50%, preferably included within 20%, more preferably included within 10%, and most preferably included within 5%. The permissible variations encompassed by the terms "about" or "approximately" depend on the specific system under study and can be readily understood by those of ordinary skill in the art.
[0103] In the present invention, the terms "above", "below", "at most" and "at least" may include the number.
[0104] Detailed Description of the Invention
[0105] In one aspect, the present invention provides a composition comprising a TIL population in which at least a portion of cells has increased cytokine expression and / or enhanced activity, and a substance that reduces the number of lymphocytes and / or maintains the proliferation ability of the TIL population.
[0106] For example, the composition of the present invention comprises a TIL population, and at least a portion of the cells in the TIL population have been modified. For example, the modification may include increasing the expression and / or activity of a cytokine in the cells. For example, increased expression and / or enhanced activity of at least one cytokine may mean that the cells do not naturally express the cytokine, but after treatment with the present invention, the cells can express various forms of the cytokine. That is, increased cytokine expression may mean that the cells naturally express no cytokine and instead express a certain amount of the cytokine. For example, the modification may be by exposing the cells to a specific substance, such as a small molecule, protein, nucleic acid, lipid, or carbohydrate. For example, the modification may be by exposing the cells to a gene editing system, such as a system that affects genomic sequence, a system that affects genomic epigenetic modifications, a system that affects gene transcription, a system that affects gene translation, and / or a system that affects post-translational modifications. For example, the cytokine of the present invention may comprise a membrane-anchored cytokine. For example, the cytokine of the present invention may comprise a modified cytokine. For example, the cytokine of the present invention may comprise a fusion protein comprising a native cytokine and a receptor for the cytokine, and / or functional variants thereof.
[0107] In one aspect, the present invention provides a kit comprising a composition of the present invention.
[0108] In one aspect, the present invention provides use of the composition of the present invention and / or the kit of the present invention in preparing a medicament for treating tumors.
[0109] In one aspect, the present invention provides a medicament for treating tumors, comprising the composition of the present invention and / or the kit of the present invention.
[0110] In one aspect, the present invention provides a method for treating tumors, comprising administering the composition of the present invention and / or the kit of the present invention to a subject in need thereof.
[0111] In one aspect, the present invention provides a composition of the present invention and / or a kit of the present invention for use in treating tumors.
[0112] According to the use of the present invention, the medicament of the present invention, the method of the present invention, and / or the pharmaceutical composition and / or kit for use according to the present invention, the tumor comprises a solid tumor.
[0113] According to the use of the present invention, the medicine of the present invention, the method of the present invention, and / or the pharmaceutical composition and / or kit for use of the present invention, the tumor comprises one or more selected from the following groups: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer and renal cancer.
[0114] In one aspect, the present invention provides a method for treating tumors using a tumor-infiltrating lymphocyte (TIL) population, the method comprising the following steps: (A) increasing the expression and / or enhancing the activity of cytokines in at least a portion of cells in a TIL population derived from tumor tissue to obtain a modified TIL population; and (B) administering a therapeutically effective amount of the modified TIL population to a subject suffering from the tumor.
[0115] cytokines
[0116] The present invention provides cytokines, including natural cytokines, mutant cytokines, and / or the above-mentioned fusion proteins. For example, the cytokines of the present invention may include substances having cytokine functions. For example, the cytokines of the present invention may include, but are not limited to, structures that only provide cytokine functions. For example, when the cytokine of the present invention is used as a fusion protein, it may include a domain having cytokine functions, it may optionally include a domain having the corresponding receptor of the cytokine, it may optionally include a transmembrane domain, or it may optionally include an intracellular domain.
[0117] For example, in the present invention, the cytokine comprises an interleukin. For example, in the present invention, the cytokine comprises a cytokine capable of activating a STAT signaling pathway. For example, in the present invention, the cytokine comprises interleukin-15 (IL-15) and / or a functionally active fragment thereof. For example, in the present invention, the cytokine comprises membrane-anchored IL-15 and / or secreted IL-15. For example, in the present invention, the cytokine comprises an IL-15 domain. For example, in the present invention, the IL-15 domain comprises the amino acid sequence shown in SEQ ID NO: 2.
[0118] For example, in the present invention, the cytokine comprises IL-15 receptor alpha (IL-15Ra) and / or a functionally active fragment thereof. For example, in the present invention, the cytokine comprises an IL-15Ra extracellular domain. For example, in the present invention, the IL-15Ra extracellular domain comprises the amino acid sequence shown in SEQ ID NO: 12. For example, in the present invention, the IL-15 domain is directly or indirectly linked to the IL-15Ra extracellular domain. For example, in the present invention, the indirect link comprises a linker. For example, in the present invention, the linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-9, (SEQ ID NO: 10) l, (alanine-proline) m, (glutamic acid-proline) n, (lysine-proline) p, and (SEQ ID NO: 11) q, and any combination thereof, wherein l, m, n, p, and q are each independently at least 1. For example, wherein l, m, n, p and q are each independently at least 1 to 20, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
[0119] For example, in the present invention, the cytokine comprises a transmembrane domain. For example, in the present invention, the transmembrane domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 13-18. For example, in the present invention, the transmembrane domain is directly or indirectly connected to the IL-15Ra extracellular domain.
[0120] For example, in the present invention, the cytokine comprises an intracellular domain. For example, in the present invention, the intracellular domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 19 to 22. For example, in the present invention, the intracellular domain is directly or indirectly connected to the transmembrane domain.
[0121] For example, in the present invention, the cytokine comprises a signal peptide domain. For example, in the present invention, the signal peptide domain comprises the amino acid sequence set forth in SEQ ID NO: 1. For example, in the present invention, the signal peptide domain is directly or indirectly linked to the IL-15 domain. For example, the signal peptide domain of the present invention may be cleaved during expression of the cytokine to the target region. For example, the cytokine structure of the present invention expressed at a membrane-anchored site may no longer have a signal peptide structure.
[0122] For example, in the present invention, the cytokine comprises the amino acid sequence shown in SEQ ID NO: 23. For example, in the TIL population of the present invention, at least a portion of the cells have increased expression and / or enhanced activity of the substance shown in SEQ ID NO: 23. For example, in the TIL population of the present invention, at least a portion of the cells express the substance shown in SEQ ID NO: 23.
[0123] For example, in the present invention, wherein the expression and / or activity enhancement of the cytokine of at least a portion of the cells in the TIL group derived from tumor tissue is increased, comprises introducing a nucleic acid encoding the cytokine into at least a portion of the cells in the TIL group derived from tumor tissue. For example, in the present invention, the nucleic acid encoding the cytokine is integrated into the cell genome. For example, in the present invention, the nucleic acid encoding the cytokine is introduced into the cell by electrotransduction. For example, in the present invention, the nucleic acid encoding the cytokine can be introduced into the cell by a transmembrane delivery system, such as liposomes, calcium ion treatment, or nanoparticles. For example, the method of genetically modifying the TIL group of the present invention includes a transposon-mediated gene transfer step. For example, the gene editing process of the present invention can include the use of programmable nucleases (such as zinc finger nucleases (ZFNs), transcription activator-like nucleases (TALENs), and CRISPR-associated nucleases) that mediate the generation of double-stranded or single-stranded breaks. This type of programmable nuclease achieves precise genome editing by introducing breaks at specific genomic sites, that is, it relies on identifying specific DNA sequences within the genome that target the nuclease domain to this position and mediate the generation of double-stranded breaks at the target sequence. Double-strand breaks in DNA subsequently recruit endogenous repair machinery to the break site to mediate genome editing through non-homologous end-joining (NHEJ) or homology-directed repair (HDR). As a result, repair of the break can result in the introduction of insertion / deletion mutations that disrupt (e.g., silence, repress, or enhance) the target gene product.
[0124] For example, in the present invention, the vector comprises a viral vector. For example, in the present invention, the viral vector comprises a retroviral vector. For example, in the present invention, the viral vector comprises a lentiviral vector.
[0125] For example, in the present invention, the expression of the cytokine is increased, including the synthesis and / or secretion of the cytokine. For example, in the present invention, compared with a TIL group in which the expression and / or activity of the cytokine is unchanged, the expression of the cytokine of at least a portion of the cells in the TIL group derived from tumor tissue is increased and / or the activity of the TIL group is enhanced, and the proportion of cells expressing the cytokine in the TIL group is increased. For example, in the present invention, compared with a TIL group in which the expression and / or activity of the cytokine is unchanged, the expression of the cytokine of at least a portion of the cells in the TIL group derived from tumor tissue is increased and / or the activity of the TIL group is enhanced, and the proportion of cells expressing the cytokine in the TIL group is increased by at least about 5%. For example, in the present invention, in a TIL group in which the expression of the cytokine of at least a portion of the cells in the TIL group derived from tumor tissue is increased and / or the activity of the TIL group is enhanced, the proportion of cells expressing the cytokine is at least about 5%. For example, in the present invention, in the modified TIL group used to a subject suffering from the tumor, the proportion of cells expressing the cytokine is at least about 5%.
[0126] For example, in the methods of the present invention, the proportion of cells expressing a cytokine in a TIL population obtained by increasing the expression and / or enhancing the activity of at least one cytokine in the TIL population can be increased by at least about 5% compared to a TIL population in which the expression and / or activity of the cytokine is not altered. For example, the proportion of cells expressing membrane-anchored IL-15 can be increased by at least about 100% to about 5%, such as at least about 100%, at least about 90%, at least about 80%, at least about 70%, at least about 60%, at least about 50%, at least about 40%, at least about 30%, at least about 20%, at least about 19%, at least about 18%, at least about 17%, at least about 16%, at least about 15%, at least about 14%, at least about 13%, at least about 12%, at least about 11%, at least about 10%, at least about 9%, at least about 8%, at least about 7%, at least about 6%, or at least about 5%. For example, the proportion of cells expressing membrane-anchored IL-15 can be increased from 0% to an observable proportion of cells. For example, the proportion of cells expressing membrane-anchored IL-15 can be increased to at least about 100% to about 5%, such as at least about 100%, at least about 90%, at least about 80%, at least about 70%, at least about 60%, at least about 50%, at least about 40%, at least about 30%, at least about 20%, at least about 19%, at least about 18%, at least about 17%, at least about 16%, at least about 15%, at least about 14%, at least about 13%, at least about 12%, at least about 11%, at least about 10%, at least about 9%, at least about 8%, at least about 7%, at least about 6%, at least about 5%, at least about 4%, at least about 3%, at least about 2%, or at least about 1%. For example, the proportion of cells expressing membrane-anchored IL-15 can be detected by flow cytometry.
[0127] For example, the proportion of cells expressing the cytokine in the TIL population obtained by increasing the expression and / or enhancing the activity of at least one cytokine in the TIL population in the methods of the present invention can be at least about 5%. For example, the proportion of cells expressing membrane-anchored IL-15 can be at least about 100% to about 5%, such as at least about 100%, at least about 90%, at least about 80%, at least about 70%, at least about 60%, at least about 50%, at least about 40%, at least about 30%, at least about 20%, at least about 19%, at least about 18%, at least about 17%, at least about 16%, at least about 15%, at least about 14%, at least about 13%, at least about 12%, at least about 11%, at least about 10%, at least about 9%, at least about 8%, at least about 7%, at least about 6%, or at least about 5%. For example, the proportion of cells expressing membrane-anchored IL-15 can be detected by flow cytometry.
[0128] For example, compared to a TIL group in which the expression and / or activity of a cytokine is unchanged, the TIL group obtained by increasing the expression and / or enhancing the activity of at least one cytokine of the TIL group can show improved TIL characteristics. For example, a TIL group in which the expression and / or activity of a cytokine is unchanged can refer to a TIL group cell derived from the same donor and having not increased the expression and / or enhanced activity of at least one cytokine of the TIL group. For example, a TIL group in which the expression and / or activity of a cytokine is unchanged can refer to a TIL group cell derived from the same donor and having not increased the expression and / or enhanced activity of a substance other than the cytokine of the TIL group (e.g., green fluorescent protein).
[0129] For example, the corresponding TIL group that has not increased the expression and / or enhanced the activity of at least one cytokine of the TIL group can refer to a TIL group cell that has been isolated in the same manner and has not increased the expression and / or enhanced the activity of at least one cytokine of the TIL group from the same donor. For example, the corresponding TIL group that has not increased the expression and / or enhanced the activity of at least one cytokine of the TIL group can refer to a TIL group cell that has not increased the expression and / or enhanced the activity of at least one cytokine of the TIL group from the same tumor source of the same donor and has not increased the expression and / or enhanced the activity of at least one cytokine of the TIL group. For example, the corresponding TIL group that has not increased the expression and / or enhanced the activity of at least one cytokine of the TIL group can refer to dividing the TIL group cells derived from the same donor into two groups, wherein one group of TIL group cells that has not increased the expression and / or enhanced the activity of at least one cytokine of the TIL group can be a corresponding TIL group that has not increased the expression and / or enhanced the activity of at least one cytokine of the TIL group. For example, increased expression and / or enhanced activity of at least one cytokine may mean that natural cells do not express the cytokine, but after treatment with the present invention, the cells can express various forms of the cytokine, that is, increased expression of the cytokine can cause natural cells to change from not expressing the cytokine to expressing a certain amount of the cytokine.
[0130] For example, the improved TIL characteristics of the present invention include one or more selected from the following groups: increased TIL cell number, increased proportion of viable cells, increased survival ability, improved T cell subset ratio, improved cytokine secretion ability, improved tumor cell killing ability, increased T cell receptor (TCR) clonal diversity and increased TIL cell number in tissue.
[0131] For example, the increased number of TIL cells in a tissue of the present invention may refer to a T cell number in a tumor tissue, blood tissue, bone marrow tissue, lung tissue and / or spleen tissue of the TIL of the present invention in which the expression and / or activity of at least one cytokine of the TIL is increased and / or enhanced in at least one in vitro expansion stage compared to the corresponding TIL in which the expression and / or activity of at least one cytokine of the TIL is not increased and / or enhanced in the in vitro expansion stage. For example, at least about 1 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 11 times, at least about 12 times, at least about 13 times, at least about 14 times, at least about 15 times, at least about 20 times, at least about 30 times, at least about 40 times, or at least about 50 times.
[0132] For example, the improved TIL cell number of the present invention refers to that the expression of at least one cytokine of the TIL is not increased and / or the activity is enhanced in the in vitro expansion stage. The cell number of the TIL of the present invention that increases and / or enhances the activity of at least one cytokine of the TIL in at least one in vitro expansion stage can be increased by at least about 1 times to about 50 times, for example, at least about 1 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 11 times, at least about 12 times, at least about 13 times, at least about 14 times, at least about 15 times, at least about 20 times, at least about 30 times, at least about 40 times, or at least about 50 times. For example, the improved TIL cell number can be expressed as an increase in TIL cell viability. For example, the increased number of TIL cells of the present invention may refer to the number of cells of the TIL of the present invention that has increased the expression and / or enhanced activity of at least one cytokine of the TIL in at least one in vitro expansion stage compared to the corresponding TIL that has not increased the expression and / or enhanced activity of at least one cytokine of the TIL in the in vitro expansion stage, which can be increased by at least about 100% to 0.1%, for example, at least about 100%, at least about 90%, at least about 80%, at least about 70%, at least about 60%, at least about 50%, at least about 40%, at least about 30%, at least about 20%, or more. 0%, at least about 19%, at least about 18%, at least about 17%, at least about 16%, at least about 15%, at least about 14%, at least about 13%, at least about 12%, at least about 11%, at least about 10%, at least about 9%, at least about 8%, at least about 7%, at least about 6%, at least about 5%, at least about 4%, at least about 3%, at least about 2%, at least about 1%, at least about 0.9%, at least about 0.8%, at least 0.7%, at least about 0.6%, at least about 0.5%, at least about 0.4%, at least about 0.3%, at least about 0.2%, or at least about 0.1%.
[0133] For example, the improved cytokine secretion capacity of the present invention can refer to the improvement of the cytokine secretion capacity of TIL cells selected from the following groups: CD107a, GZMB, IL-2, TNF-α and IFN-γ. For example, the improved cytokine secretion capacity of the present invention can refer to the improvement of the expression of at least one cytokine of the TIL and / or the activity of the corresponding TIL that has not been increased in the in vitro expansion stage, and the cytokine secretion capacity of the TIL of the present invention that has been increased and / or the activity of the TIL of the present invention can be increased by at least about 1 times to about 50 times, for example, at least about 1 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 11 times, at least about 12 times, at least about 13 times, at least about 14 times, at least about 15 times, at least about 20 times, at least about 30 times, at least about 40 times, or at least about 50 times. For example, the improved cytokine secretion capacity of the present invention may mean that the cytokine secretion capacity of the TIL of the present invention in which the expression and / or activity of at least one cytokine of the TIL has been increased in at least one in vitro expansion stage is increased by at least about 100% to 0.1%, for example, at least about 100%, at least about 90%, at least about 80%, at least about 70%, at least about 60%, at least about 50%, at least about 40%, at least about 30%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, at least about 200%, at least about 210%, at least about 220%, at least about 230%, at least about 240%, at least about 250%, at least about 260%, at least about 270%, at least about 280%, at least about 290%, at least about 300%, at least about 310%, at least about 320%, at least about 330%, at least about 340%, at least about 350%, at least about 360%, at least about 370%, at least about 380%, at least about 390%, at least about 400%, at least about 410%, at least about 420%, at least about 430%, at least about 440%, at least about 450%, at least about 460%, at least about 470%, at least about 480%, at least about 490%, at least about 500%, at least At least about 20%, at least about 19%, at least about 18%, at least about 17%, at least about 16%, at least about 15%, at least about 14%, at least about 13%, at least about 12%, at least about 11%, at least about 10%, at least about 9%, at least about 8%, at least about 7%, at least about 6%, at least about 5%, at least about 4%, at least about 3%, at least about 2%, at least about 1%, at least about 0.9%, at least about 0.8%, at least about 0.7%, at least about 0.6%, at least about 0.5%, at least about 0.4%, at least about 0.3%, at least about 0.2% or at least about 0.1%. For example, the cytokine secretion capacity of the TIL of the present invention can be determined by measuring the cytokine expression capacity of TIL cells. For example, the cytokine secretion capacity of the TIL of the present invention is determined by measuring the cytokine release capacity of TIL cells. For example, the cytokine secretion capacity of the TIL of the present invention is determined by CBA method (Cytometric Bead Array).
[0134] For example, the increased NK cell ratio of the present invention may be an increase in the ratio of NK cells in TIL cells. For example, the proportion of NK cells in TIL cells can be increased by at least about 100% to 0.1%, such as at least about 100%, at least about 90%, at least about 80%, at least about 70%, at least about 60%, at least about 50%, at least about 40%, at least about 30%, at least about 20%, at least about 19%, at least about 18%, at least about 17%, at least about 16%, at least about 15%, at least about 14%, at least about 13%, at least about 12%, at least about 11%, at least about 10%, at least about 9%, at least about 8%, at least about 7%, at least about 6%, at least about 5%, at least about 4%, at least about 3%, at least about 2%, at least about 1%, at least about 0.9%, at least about 0.8%, at least 0.7%, at least about 0.6%, at least about 0.5%, at least about 0.4%, at least about 0.3%, at least about 0.2%, or at least about 0.1%.
[0135] For example, the improved tumor cell killing ability of the present invention may mean that the tumor cell killing rate of the TIL of the present invention in which the expression and / or activity of at least one cytokine of the TIL is increased and / or enhanced in at least one in vitro expansion stage is increased by at least about 1 times to about 50 times, for example, at least about 1 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 11 times, at least about 12 times, at least about 13 times, at least about 14 times, at least about 15 times, at least about 20 times, at least about 30 times, at least about 40 times, or at least about 50 times, compared to the corresponding TIL in which the expression and / or activity of at least one cytokine of the TIL was not increased and / or the activity was enhanced in at least one in vitro expansion stage. For example, the improved tumor cell killing ability of the present invention may mean that the tumor cell killing rate of the TIL of the present invention in which the expression and / or activity of at least one cytokine of the TIL is increased in at least one in vitro expansion stage is increased by at least about 100% to 0.1%, for example, at least about 100%, at least about 90%, at least about 80%, at least about 70%, at least about 60%, at least about 50%, at least about 40%, at least about 30%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 160%, at least about 170%, at least about 180%, at least about 190%, at least about 200%, at least about 210%, at least about 220%, at least about 230%, at least about 240%, at least about 250%, at least about 260%, at least about 270%, at least about 280%, at least about 290%, at least about 300%, at least about 310%, at least about 320%, at least about 330%, at least about 340%, at least about 350%, at least about 360%, at least about 370%, at least about 380%, at least about 390%, at least about 400%, at least about 410%, at least about 420%, at least about 430%, at least about 440%, at least about 450%, at least about 460%, at least about 470%, at least about 480%, at least about 490%, at least about 500%, at least about About 20%, at least about 19%, at least about 18%, at least about 17%, at least about 16%, at least about 15%, at least about 14%, at least about 13%, at least about 12%, at least about 11%, at least about 10%, at least about 9%, at least about 8%, at least about 7%, at least about 6%, at least about 5%, at least about 4%, at least about 3%, at least about 2%, at least about 1%, at least about 0.9%, at least about 0.8%, at least 0.7%, at least about 0.6%, at least about 0.5%, at least about 0.4%, at least about 0.3%, at least about 0.2%, or at least about 0.1%. For example, the tumor cell killing rate of the TIL of the present invention can be measured by CFSE and DAPI staining. For example, the tumor cell killing rate of the TIL of the present invention can be measured by using the IncuCyte system to measure Caspase-3 / 7 activity. For example, the tumor cell killing of the TIL of the present invention can refer to the ability of the TIL to kill solid tumor cells. For example, tumor cell killing by TIL of the present invention may refer to the ability of TIL to kill cervical cancer cells.
[0136] For example, the increased T cell receptor (TCR) clonal diversity of the present invention can include, during long-term culture, a greater variety of TCRs expressed in a TIL cell population of the present invention in which the expression and / or activity of at least one cytokine of the TIL has been increased in at least one in vitro expansion stage, compared to a corresponding TIL in which the expression and / or activity of at least one cytokine of the TIL has not been increased in the in vitro expansion stage, for example, an increase of at least about 100% to 0.1%, such as at least about 100%, at least about 90%, at least about 80%, at least about 70%, at least about 60%, at least about 50%, at least about 10 ... about 40%, at least about 30%, at least about 20%, at least about 19%, at least about 18%, at least about 17%, at least about 16%, at least about 15%, at least about 14%, at least about 13%, at least about 12%, at least about 11%, at least about 10%, at least about 9%, at least about 8%, at least about 7%, at least about 6%, at least about 5%, at least about 4%, at least about 3%, at least about 2%, at least about 1%, at least about 0.9%, at least about 0.8%, at least 0.7%, at least about 0.6%, at least about 0.5%, at least about 0.4%, at least about 0.3%, at least about 0.2%, or at least about 0.1%.
[0137] For example, the improved T cell subset ratio of the present invention may comprise one or more selected from the following groups: increased CD4 + Cell ratio, reduced CD8 + The results showed that the proportion of T cells increased, the proportion of central memory T cells decreased, the proportion of regulatory T cells decreased, the proportion of activated T cells increased, the proportion of tumor-specific T cells increased, and the proportion of stem-like T cells increased.
[0138] Treatment options
[0139] For example, the present invention further includes reducing the number of lymphocytes in a subject suffering from the tumor before administering the modified TIL population to the subject. For example, the present invention further includes reducing the number of lymphocytes in the subject before administering the TIL obtained by the culture method to the subject. For example, in order to improve the therapeutic effect of the TIL of the present invention, the subject's lymphatic system and / or lymphocytes can be treated. For example, the subject's lymphocytes can be cleared or substantially cleared, the subject's lymphocytes can be depleted or substantially depleted, the subject's lymphocytes can be depleted or substantially depleted, or the subject's lymphocytes can be depleted or substantially depleted. For example, the treatment of the present invention can reduce the number of lymphocytes in a subject by at least about 100% to 0.1%, such as at least about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, at least about 0.9%, at least about 0.8%, at least 0.7%, at least about 0.6%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, or about 0.1%, relative to before treatment. For example, the present invention can reduce the number of lymphocytes in the subject by comprising a lymphoablative regimen.
[0140] For example, in the present invention, the method further comprises administering cyclophosphamide and / or fludarabine to a subject suffering from the tumor before administering the modified TIL population to the subject.
[0141] For example, in the present invention, the method further comprises administering cyclophosphamide and / or fludarabine to a subject having the tumor from day 4 to day 2 before administering the modified TIL population to the subject.
[0142] For example, about 50 to about 500 mg / m 2 Cyclophosphamide may be administered to the subject at a dose of about 50 mg / m 2 / day, about 100 mg / m 2 / day, about 150mg / m 2 / day, about 200 mg / m 2 / day, about 250mg / m 2 / day, about 300 mg / m 2 / day, about 350 mg / m 2 / day, about 400 mg / m 2 / day, about 450mg / m 2 / day, or about 500 mg / m 2The dosage is preferably about 300-500 mg / m 2 The subject may be administered cyclophosphamide at a dose of 1 mg / day. For example, the subject may be administered cyclophosphamide for 3 days. For example, the subject may be administered cyclophosphamide from day 4 to day 2 prior to administering TIL.
[0143] For example, the dosage may be from about 5 to about 30 mg / m 2 Fludarabine may be administered to the subject at a dose of about 5 mg / m 2 / day, about 10 mg / m 2 / day, about 15mg / m 2 / day, about 20 mg / m 2 / day, about 25mg / m 2 / day, or about 30 mg / m 2 / day dosage, preferably about 20-30 mg / m 2 The subject is administered fludarabine at a dosage of 1:1 or 2 days. For example, the subject may be administered fludarabine for 3 days. For example, the subject may be administered fludarabine from day 4 to day 2 before administering TIL.
[0144] In some embodiments, the number of TILs provided in the compositions of the present invention may range from about 5×10 9 to 1×10 11 , for example, about 5×10 9 to 1×10 10 , about 1×10 10 to 5×10 10 , or about 5×10 10 to 1×10 11 In some embodiments, the number of TILs provided in the compositions of the present invention may range from about 5×10 9 , about 1×10 10 , about 5×10 10 , or about 1×10 11 For example, the method may comprise administering the modified TIL population to the subject by a single intravenous infusion. For example, the method may comprise administering the modified TIL population to the subject by multiple intravenous infusions. For example, in the present invention, the method may further comprise administering the modified TIL population to the subject by a single intravenous infusion. 9 or higher cell number of the modified TIL population for use in a subject having the tumor.
[0145] For example, the present invention also includes administering the modified TIL population to a subject suffering from the tumor via a one-time intravenous infusion.
[0146] For example, the present invention further comprises maintaining the proliferation capacity of the modified TIL population after administering the modified TIL population to a subject suffering from the tumor. For example, the present invention further comprises administering interleukin-2 (IL-2) or a variant thereof to the subject after administering the modified TIL population to the subject suffering from the tumor.
[0147] For example, IL-2 can be administered to the subject at a dosage of about 100,000 to about 600,000 IU / kg / time.For example, IL-2 can be administered to the subject at a dosage of about 100,000 IU / kg / time, about 200,000 IU / kg / time, about 300,000 IU / kg / time, about 400,000 IU / kg / time, about 500,000 IU / kg / time, or about 600,000 IU / kg / time.
[0148] For example, in the present invention, the method further comprises administering IL-2 to the subject for the first time 8 to 16 hours after administering the modified TIL population to the subject having the tumor.
[0149] For example, in the present invention, after the first administration of IL-2 to the subject, IL-2 is administered to the subject every 12 hours.
[0150] For example, after the first administration of IL-2 to the subject, IL-2 may be administered to the subject once every 12 hours. For example, after the first administration of IL-2, administration of IL-2 may be suspended once; for example, the determination of whether to continue administering IL-2 may be based on the patient's tolerance. For example, 24 hours after the first administration of IL-2 to the subject, the IL-2 may be administered a second time based on the subject's tolerance. For example, the determination of whether to continue administering IL-2 may be based on the subject's adverse reactions. For example, IL-2 may be administered to the subject 10 or fewer times.
[0151] Cell culture process
[0152] For example, in the present invention, the method further comprises: subjecting a TIL population derived from a tumor tissue to at least a first stage of in vitro expansion and a second stage of in vitro expansion, and co-culturing the TIL population with feeder cells during the second stage of in vitro expansion. In one embodiment, during a single stage of in vitro expansion according to the present invention, the expression and / or activity of at least one cytokine of the TILs can be increased and / or enhanced, and the TILs can be co-cultured with the feeder cells of the present invention. In one embodiment, a single stage of in vitro expansion according to the present invention can refer to in vitro expansion according to the present invention at the same stage, for example, the first stage of in vitro expansion according to the present invention, the second stage of in vitro expansion according to the present invention, or the third stage of in vitro expansion according to the present invention. In one embodiment, during the first stage of in vitro expansion according to the present invention, the expression and / or activity of at least one cytokine of the TILs can be increased and / or enhanced, and the TILs can be co-cultured with the feeder cells of the present invention. In one embodiment, during the second stage of in vitro expansion according to the present invention, the expression and / or activity of at least one cytokine of the TILs can be increased and / or enhanced, and the TILs can be co-cultured with the feeder cells of the present invention. In one embodiment, in the third stage of in vitro expansion of the present invention, the expression and / or activity of at least one cytokine of the TIL can be increased and / or enhanced, and the TIL can be co-cultured with the feeder cells of the present invention.
[0153] In one embodiment, each stage of in vitro expansion can be divided by the change in the number of TIL cells. In one embodiment, when the number of TIL cells increases by at least about 1 times, it can be considered that the TIL cells have entered the next stage of in vitro expansion. For example, when the number of TIL cells increases by at least about 1 times to at least about 1000 times, such as at least about 1 times, at least about 2 times, at least about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least about 11 times, at least about 12 times, at least about 13 times, at least about 14 times, at least about 15 times, at least about 20 times, at least about 30 times, at least about 40 times, at least about 50 times, at least about 100 times, at least about 200 times, at least about 500 times, or at least about 1000 times, it can be considered that the TIL cells have entered the next stage of in vitro expansion. In one embodiment, each stage of in vitro expansion can also be divided by changes in the conditions of TIL cell culture. In one embodiment, when a T cell activator and / or a T cell growth factor is added to or supplemented with the cell culture medium, it can be considered that the TIL cells have entered the next stage of in vitro expansion. For example, when IL-2 is added to or supplemented with the cell culture medium, it can be considered that the TIL cells have entered the next stage of in vitro expansion. For example, the expression and / or activity of at least one cytokine of the TIL is increased, and it can be considered that the TIL cells have entered the next stage of in vitro expansion. For example, when feeder cells are added to or supplemented with the cell culture medium, it can be considered that the TIL cells have entered the next stage of in vitro expansion. In one embodiment, after the TIL cells have been centrifuged and / or washed, it can be considered that the TIL cells have entered the next stage of in vitro expansion. In one embodiment, each stage can also be divided by the number of days the TIL cells are cultured. In one embodiment, after the TIL cells are cultured in vitro for about 1 day to about 100 days, for example, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 30 days, about 40 days, about 50 days or about 100 days, the TIL cells can be considered to have entered the next stage of in vitro expansion.
[0154] For example, the second stage in vitro amplification can be performed for at least about 7 days. For example, the second stage in vitro amplification can be performed for at least about 9 days. For example, the second stage in vitro amplification can be performed for up to about 14 days. For example, the second stage in vitro amplification can be performed for up to about 13 days. For example, the second stage in vitro amplification can be performed for about 7 days to about 14 days, about 9 days to about 14 days, about 7 days to about 13 days, or about 9 days to about 13 days. For example, the second stage in vitro amplification of the present invention can be performed for at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, or at least about 14 days. For example, the second stage in vitro expansion of the present invention can be performed for about 9 days to about 14 days, about 10 days to about 14 days, about 11 days to about 14 days, about 12 days to about 14 days, about 13 days to about 14 days, about 9 days to about 13 days, about 10 days to about 13 days, about 11 days to about 13 days, about 12 days to about 13 days, about 9 days to about 12 days, about 10 days to about 12 days, about 11 days to about 12 days, or about 10 days to about 11. For example, the second stage in vitro expansion of the present invention can be considered the REP (rapid expansion protocol) stage.
[0155] For example, the first stage in vitro expansion can be carried out for at least about 7 days. For example, the first stage in vitro expansion can be carried out for about 7 days to about 14 days. For example, the first stage in vitro expansion of the present invention can be carried out for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, or at least about 14 days. For example, the first stage in vitro expansion of the present invention can be carried out for about 7 days to about 14 days, about 8 days to about 14 days, about 9 days to about 14 days, about 10 days to about 14 days, about 11 days to about 14 days, about 12 days to about 14 days, about 13 days to about 14 days, about 9 days to about 13 days, about 10 days to about 13 days, about 11 days to about 13 days, about 12 days to about 13 days, about 9 days to about 12 days, about 10 days to about 12 days, about 11 days to about 12 days, or about 10 days to about 11 days. For example, the first stage in vitro expansion of the present invention can be considered the preREP stage.
[0156] In one embodiment, the number of days that the second stage in vitro amplification of the present invention is performed can be calculated from the start of the second stage in vitro amplification. For example, when the second stage in vitro amplification starts, it can be considered that the second stage in vitro amplification has been performed for about 0 days. For example, about 24 hours after the start of the second stage in vitro amplification, it can be considered that the second stage in vitro amplification has been performed for about 1 day. For example, the day the second stage in vitro amplification starts can be considered that the second stage in vitro amplification has been performed for about 0 days. In one embodiment, the number of days that the second stage in vitro amplification of the present invention is performed can be calculated from the start of the second stage in vitro amplification. For example, the day after the second stage in vitro amplification starts, it can be considered that the second stage in vitro amplification has been performed for about 1 day.
[0157] In one embodiment, the culture method of the present invention can be divided according to a two-step division method. For example, (A) a first TIL group derived from a tumor tissue and not amplified in vitro can be contacted with a T cell growth factor, wherein a second TIL group is obtained by step (A); (B) the expression and / or activity of at least one cytokine of the second TIL group can be increased, and the second TIL group is co-cultured with feeder cells after contacting with a T cell activator and / or T cell growth factor for a certain period of time, wherein a third TIL group is obtained by step (B). For example, step (A) can be performed for about 7 days to about 14 days. For example, step (B) can be performed for about 7 days to about 14 days.
[0158] In one embodiment, the culture method of the present invention can be divided according to a three-step division method. For example, (A) a first TIL group derived from a tumor tissue and not amplified in vitro can be contacted with a T cell growth factor, wherein a second TIL group is obtained through step (A); (B) the expression and / or activity of at least one cytokine of the second TIL group can be increased, and the second TIL group can be contacted with a T cell activator and / or a T cell growth factor, wherein a third TIL group is obtained through step (B); (C) the third TIL group can be co-cultured with feeder cells, wherein a fourth TIL group is obtained through step (C). For example, step (A) can be performed for about 7 days to about 14 days. For example, step (B) can be performed for about 0 days to about 8 days. For example, step (C) can be performed for about 5 days to about 14 days.
[0159] In one embodiment, the culture method of the present invention can be divided according to a four-step division method. For example, (A) a first TIL group derived from a tumor tissue and not amplified in vitro can be contacted with a T cell growth factor, wherein a second TIL group is obtained through step (A); (B) the second TIL group can be contacted with a T cell activator and / or a T cell growth factor, wherein a third TIL group is obtained through step (B); (C) the expression and / or activity of at least one cytokine of the third TIL group can be increased, wherein a fourth TIL group is obtained through step (C); (D) the fourth TIL group can be co-cultured with feeder cells, wherein a fifth TIL group is obtained through step (D). For example, step (A) can be performed for about 7 days to about 14 days. For example, step (B) can be performed for about 0 days to about 4 days. For example, step (C) can be performed for about 0 days to about 4 days. For example, step (D) can be performed for about 5 days to about 14 days.
[0160] In one embodiment, step (A) of the culture method of the present invention is to obtain a second TIL group from the recovery and / or continued cultivation of the in vitro TIL group. For example, the in vitro TIL group may include a TIL group obtained by in vitro amplification of a first TIL group derived from tumor tissue and without in vitro amplification. For example, the in vitro TIL group may include a TIL group obtained by contacting the first TIL group with a T cell growth factor. For example, the in vitro TIL group may include a TIL group obtained by cryopreservation of the first TIL group. For example, the in vitro TIL group may include a TIL group obtained by contacting the first TIL group with a T cell growth factor and cryopreservation. For example, when step (A) of the present invention is to obtain a second TIL group from the recovery and / or continued cultivation of the in vitro TIL group, step (A) can be performed for about 2 hours to about 4 days.
[0161] In one embodiment, in the in vitro expansion of the present invention in a single stage, the TIL of the present invention can be contacted with one or more T cell activators and / or one or more T cell growth factors of the present invention for a certain period of time, and then co-cultured with the feeder cells of the present invention. In one embodiment, the certain period of time of the present invention can be at least about 1 hour. In one embodiment, the certain period of time of the present invention can be, for example, at least about 1 hour to at least about 72 hours, at least about 1 hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, at least about 6 hours, at least about 7 hours, at least about 8 hours, at least about 9 hours, at least about 10 hours, at least about 11 hours, at least about 12 hours, at least about 13 hours, at least about 14 hours, at least about 15 hours, at least about 16 hours, at least about 17 hours, at least about 18 hours, at least about 19 hours, at least about 20 hours, at least about 21 hours, at least about 22 hours, at least about 23 hours, at least about 24 hours, at least about 36 hours, at least about 48 hours, at least about 60 hours or at least about 72 hours. In one embodiment, the certain time of the present invention can be from about 6 hours to about 72 hours. In one embodiment, the certain time of the present invention can be from about 6 hours to about 7 hours, from about 6 hours to about 8 hours, from about 6 hours to about 9 hours, from about 6 hours to about 10 hours, from about 6 hours to about 11 hours, from about 6 hours to about 12 hours, from about 6 hours to about 13 hours, from about 6 hours to about 14 hours, from about 6 hours to about 15 hours, from about 6 hours to about 16 hours, from about 6 hours to about 17 hours, from about 6 hours to about 18 hours, from about 6 hours to about 19 hours, from about 6 hours to about 20 hours, from about 6 hours to about 21 hours, from about 6 hours to about 22 hours, from about 6 hours to about 23 hours, from about 6 hours to about 24 hours, from about 6 hours to about 36 hours, from about 6 hours to about 48 hours, from about 6 hours to about 60 hours, or from about 6 hours to about 72 hours. In one embodiment, the certain period of time of the present invention can be about 12 hours to about 13 hours, about 12 hours to about 14 hours, about 12 hours to about 15 hours, about 12 hours to about 16 hours, about 12 hours to about 17 hours, about 12 hours to about 18 hours, about 12 hours to about 19 hours, about 12 hours to about 20 hours, about 12 hours to about 21 hours, about 12 hours to about 22 hours, about 12 hours to about 23 hours, about 12 hours to about 24 hours, about 12 hours to about 36 hours, about 12 hours to about 48 hours, about 12 hours to about 60 hours, or about 12 hours to about 72 hours.In one embodiment, the certain period of time of the present invention can be about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours or about 72 hours.
[0162] In one embodiment, the feeder cells of the present invention may comprise antigen presenting cells. In one embodiment, the feeder cells of the present invention may comprise one or more selected from the following groups: peripheral mononuclear cells, dendritic cells, and artificial antigen presenting cells. In one embodiment, the feeder cells of the present invention may be peripheral mononuclear cells. In one embodiment, the feeder cells of the present invention may be irradiated feeder cells. For example, the feeder cells of the present invention may be isolated artificial antigen presenting cells (aAPCs), which may comprise cells expressing HLA-A / B / C, CD64, CD80, ICOS-L and / or CD58, and may be modified to express one or more T cell activators of the present invention. In one embodiment, the feeder cells of the present invention may be irradiated, for example, may be irradiated with gamma rays, or may be irradiated with X rays.
[0163] In one embodiment, co-culturing the TILs of the present invention with the feeder cells of the present invention may comprise contacting the surface of the feeder cells of the present invention with the surface of the TILs of the present invention. In one embodiment, co-culturing the TILs of the present invention with the feeder cells of the present invention comprises adding the feeder cells of the present invention to the cell culture medium of the TILs of the present invention.
[0164] In one embodiment, the present invention can add the feeder cells of the present invention to the cell culture medium of the TIL of the present invention at a ratio of about 40: 1 to about 400: 1. In one embodiment, the present invention can add the feeder cells of the present invention to the cell culture medium of the TIL of the present invention at a ratio of about 40: 1 to about 400: 1, about 40: 1 to about 300: 1, about 40: 1 to about 200: 1, about 40: 1 to about 100: 1, about 40: 1 to about 90: 1, about 40: 1 to about 80: 1, about 40: 1 to about 70: 1, about 40: 1 to about 60: 1, about 40: 1 to about 50: 1, about 50: 1 to about 400: 1. 1. Adding the feeder cells of the present invention to the cell culture medium of the TILs of the present invention at a ratio of about 60:1 to about 400:1, about 70:1 to about 400:1, about 80:1 to about 400:1, about 90:1 to about 400:1, about 100:1 to about 400:1, about 200:1 to about 400:1, or about 300:1 to about 400:1 of the feeder cells of the present invention to the TILs of the present invention.
[0165] In one embodiment, the method of the present invention may further comprise: subjecting TILs derived from tumor tissue and not expanded in vitro to at least one stage of in vitro expansion, wherein, in at least one stage of in vitro expansion of the present invention, the TILs of the present invention are contacted with one or more T cell activators.
[0166] In one embodiment, during a single stage of in vitro expansion of the present invention, the TILs are contacted with the one or more T cell activators. For example, the T cell activator may comprise an agonist of one or more targets selected from the following group: CD3, CD28, HVEM, CD40L, OX40, and 4-1BB. In one embodiment, during a single stage of in vitro expansion, the expression of at least one cytokine of the TILs is increased and / or the activity is enhanced, and the TILs are contacted with one or more T cell activators of the present invention. In one embodiment, during the first stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TILs may be increased and / or the activity is enhanced, and the TILs are contacted with one or more T cell activators of the present invention. In one embodiment, during the second stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TILs may be increased and / or the activity is enhanced, and the TILs are contacted with one or more T cell activators of the present invention. In one embodiment, during the third stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TILs may be increased and / or the activity is enhanced, and the TILs are contacted with one or more T cell activators of the present invention.
[0167] In one embodiment, in a single stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TIL can be increased and / or the activity is enhanced and the TIL is contacted with one or more T cell activators of the present invention at substantially the same time. In one embodiment, in a single stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TIL can be increased and / or the activity is enhanced first, for example, 2 hours to 48 hours in advance, for example, 2 hours in advance, 4 hours in advance, 8 hours in advance, 12 hours in advance, 24 hours in advance, or 48 hours in advance, etc., and then contacted with one or more T cell activators of the present invention. In one embodiment, in a single stage of in vitro expansion of the present invention, the TIL of the present invention can be contacted with one or more T cell activators of the present invention first, for example, 2 hours to 48 hours in advance, for example, 2 hours in advance, 4 hours in advance, 8 hours in advance, 12 hours in advance, 24 hours in advance, or 48 hours in advance, etc., and then the expression of at least one cytokine of the TIL can be increased and / or the activity is enhanced.
[0168] In one embodiment, in the first stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TIL can be increased and / or the activity is enhanced and the TIL is contacted with one or more T cell activators of the present invention at substantially the same time. In one embodiment, in the second stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TIL can be increased and / or the activity is enhanced and the TIL is contacted with one or more T cell activators of the present invention at substantially the same time. In one embodiment, in the third stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TIL can be increased and / or the activity is enhanced and the TIL is contacted with one or more T cell activators of the present invention at substantially the same time.
[0169] In one embodiment, the T cell activator of the present invention may comprise one or more selected from the following group: CD80, CD86, B7-H3, 4-1BBL, CD27, CD30, CD134, B7h, CD40, LIGHT, and functionally active fragments thereof. In one embodiment, the T cell activator of the present invention may comprise an agonist of one or more targets selected from the following group: CD3, CD28, HVEM, CD40L, OX40, and 4-1BB. In one embodiment, the T cell activator of the present invention may comprise an antibody selected from the following group: CD3, CD28, HVEM, CD40L, OX40, and 4-1BB, and an antigen-binding fragment thereof. In one embodiment, the T cell activator of the present invention may comprise a CD3 agonist. In one embodiment, the T cell activator of the present invention may comprise an anti-CD3 antibody and / or an antigen-binding fragment thereof, such as OKT3 from Miltenyi Biotech or SP34 from BD. In one embodiment, the T cell activator of the present invention may comprise a CD28 agonist. In one embodiment, the T cell activator of the present invention may comprise an anti-CD28 antibody and / or an antigen-binding fragment thereof, such as Merck's 15E8. The T cell activator of the present invention may comprise CD80 and / or a functionally active fragment thereof and / or CD86 and / or a functionally active fragment thereof, as well as recombinant proteins of the above substances.
[0170] In one embodiment, the T cell activator of the present invention may comprise an anti-CD3 antibody and / or antigen-binding fragment thereof, for example, the light chain VL and heavy chain VH of Miltenyi Biotech's OKT3, or the light chain VL and heavy chain VH of BD's SP34. In one embodiment, the T cell activator of the present invention may comprise a CD28 agonist. In one embodiment, the T cell activator of the present invention may comprise an anti-CD28 antibody and / or antigen-binding fragment thereof, for example, the light chain VL and heavy chain VH of Merck's 15E8. In one embodiment, the T cell activator of the present invention may comprise an anti-CD3 antibody and / or antigen-binding fragment thereof, for example, the light chain LCDR1-3 and heavy chain HCDR1-3 of Miltenyi Biotech's OKT3, or the light chain LCDR1-3 and heavy chain HCDR1-3 of BD's SP34. The anti-CD3 antibody and / or antigen-binding fragment thereof of the present invention may have CD3 binding ability. In one embodiment, the T cell activator of the present invention may comprise a CD28 agonist. In one embodiment, the T cell activator of the present invention may comprise an anti-CD28 antibody and / or antigen-binding fragment thereof, for example, may comprise the light chain LCDR1-3 and heavy chain HCDR1-3 of Merck's 15E8. The anti-CD28 antibody and / or antigen-binding fragment thereof of the present invention may have CD28 binding ability. In the present invention, the antibody or antigen-binding protein thereof of the present invention comprises at least one CDR in the antibody heavy chain variable region VH. The CDRs of the present invention may be defined according to the IMGT nomenclature, the Chothia definition, or the Kabat definition.
[0171] In one embodiment, the CD3 agonist of the present invention can be a CD3 antibody or an antigen-binding protein thereof. In one embodiment, the CD28 agonist of the present invention can be a CD28 antibody or an antigen-binding protein thereof. In the present invention, the antibody or antigen-binding protein of the present invention comprises at least one CDR in the antibody heavy chain variable region VH. The CDRs of the present invention can be defined according to the IMGT nomenclature, the CDRs of the present invention can be defined according to Chothia, or the CDRs of the present invention can be defined according to Kabat.
[0172] For example, in the present invention, contacting the TIL population with the T cell activator comprises one or more methods selected from the following groups: (1) adding the T cell activator to the cell culture medium of the TIL population; (2) adding engineered cells expressing the T cell activator to the cell culture medium of the TIL population; and (3) adding a solid phase medium containing the T cell activator to the cell culture medium of the TIL population.
[0173] In one embodiment, the initial concentration of the T cell activator in the cell culture medium of the TIL of the present invention can be at least about 30 ng / mL. For example, the initial concentration of the CD28 antibody of the present invention in the cell culture medium of the TIL of the present invention can be at least about 30 ng / mL; for example, the initial concentration of the CD3 antibody of the present invention in the cell culture medium of the TIL of the present invention can be at least about 30 ng / mL. For example, the selection of the initial concentration of the CD28 antibody of the present invention can be independent of the selection of the initial concentration of the CD3 antibody of the present invention; for example, the initial concentrations of the CD28 antibody of the present invention and the CD3 antibody of the present invention in the cell culture medium of the TIL of the present invention can be arbitrarily combined. For example, the initial concentration of the CD28 antibody of the present invention in the cell culture medium of the TIL of the present invention can be arbitrarily selected from about 30 ng / mL to about 300 ng / mL. For example, the initial concentration of the CD3 antibody of the present invention in the cell culture medium of the TIL of the present invention can be arbitrarily selected from about 30 ng / mL to about 300 ng / mL. For example, the initial concentration of the CD28 antibody of the present invention in the cell culture medium of the TIL of the present invention can be arbitrarily selected from about 30 ng / mL to about 300 ng / mL, and the initial concentration of the CD3 antibody of the present invention in the cell culture medium of the TIL of the present invention can be arbitrarily selected from about 30 ng / mL to about 300 ng / mL, and the selection of the initial concentration of the CD28 antibody of the present invention can be independent of the selection of the initial concentration of the CD3 antibody of the present invention. In one embodiment, the diameter of the solid phase medium of the present invention can be about 500 nanometers to about 10 microns. In one embodiment, the diameter of the solid phase medium of the present invention can be measured by transmission electron microscopy. In one embodiment, the diameter of the solid phase medium of the present invention can be about 1 nanometer to about 500 nanometers. In one embodiment, the diameter of the solid phase medium of the present invention can be about 100 nanometers to about 500 nanometers. In one embodiment, the diameter of the solid phase medium of the present invention can be about 200 nanometers to about 500 nanometers. In one embodiment, the diameter of the solid phase medium of the present invention can be measured by transmission electron microscopy.
[0174] In one embodiment, the solid phase medium of the present invention may comprise a polymer. In one embodiment, the solid phase medium of the present invention may comprise dextran. In one embodiment, each mg of the solid phase medium of the present invention comprises at least about 25 μg of the T cell activator of the present invention.
[0175] In one embodiment, the solid phase medium comprising the T cell activator of the present invention is added to the cell culture medium of the TILs of the present invention at a ratio of about 100:1 to about 1:2000, for example, about 1:100 to about 1:2000. In one embodiment, the solid phase medium comprising the T cell activator of the present invention is preferably added to the cell culture medium of the TILs of the present invention at a ratio of about 2:1 to about 1:2.
[0176] For example, when the diameter of the solid phase medium of the present invention is about 100 nanometers to about 500 nanometers, the solid phase medium containing the T cell activator of the present invention can be added to the cell culture medium of the TIL of the present invention at a ratio of about 2: 1 to about 1: 2 of the solid phase medium of the present invention to the TIL of the present invention. For example, when the diameter of the solid phase medium of the present invention is about 100 nanometers to about 500 nanometers, the solid phase medium containing the T cell activator of the present invention, such as a CD3 agonist and / or a CD28 agonist, can be added to the cell culture medium of the TIL of the present invention at a ratio of about 2: 1 to about 1: 2, about 2: 1 to about 1: 1, or about 1: 1 to about 1: 2 of the solid phase medium of the present invention to the TIL of the present invention.
[0177] For example, when the diameter of the solid phase medium of the present invention is about 100 nm to about 500 nm, the solid phase medium containing the T cell activator of the present invention can be added to the cell culture medium of the TIL of the present invention at a ratio of about 1:100 to about 1:2000. For example, when the diameter of the solid phase medium of the present invention is about 100 nm to about 500 nm, the solid phase medium containing the T cell activator of the present invention can be added to the cell culture medium of the TIL of the present invention at a ratio of about 1:100 to about 1:2000, about 1:200 to about 1:2000, about 1:300 to about 1:2000, about 1:400 to about 1:2000, about 1:500 to about 1:2000, about 1:600 to about 1:2000, about 1:700 to about 1:2000, about 1:800 to about 1:2000, about For example, a solid phase medium comprising a CD28 agonist and a CD3 agonist of the present invention can be added to the cell culture medium of the TIL of the present invention at a ratio of the solid phase medium of the present invention to the TIL of the present invention of 1:900 to about 1:2000, about 1:1000 to about 1:2000, about 1:1200 to about 1:2000, about 1:1400 to about 1:2000, about 1:1600 to about 1:2000, or about 1:1800 to about 1:2000.
[0178] In one embodiment, the method of the present invention may further comprise: subjecting TILs derived from tumor tissue and not expanded in vitro to at least one stage of in vitro expansion, wherein, in at least one stage of in vitro expansion of the present invention, the TILs of the present invention are contacted with one or more T cell growth factors.
[0179] In one embodiment, in a single stage of in vitro expansion of the present invention, the TIL of the present invention can be contacted with the T cell activator of the present invention and with one or more T cell growth factors of the present invention. For example, in the first stage of in vitro expansion of the present invention, the TIL of the present invention can be contacted with the T cell activator of the present invention and with one or more T cell growth factors of the present invention. For example, in the second stage of in vitro expansion of the present invention, the TIL of the present invention can be contacted with the T cell activator of the present invention and with one or more T cell growth factors of the present invention. For example, in the third stage of in vitro expansion of the present invention, the TIL of the present invention can be contacted with the T cell activator of the present invention and with one or more T cell growth factors of the present invention.
[0180] In one embodiment, in a single stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TIL can be increased and / or the activity is enhanced and the TIL is contacted with a T cell growth factor at substantially the same time. In one embodiment, in a single stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TIL can be increased and / or the activity is enhanced, for example, 2 hours to 48 hours in advance, for example, 2 hours in advance, 4 hours in advance, 8 hours in advance, 12 hours in advance, 24 hours in advance, or 48 hours in advance, etc., and then the TIL of the present invention is contacted with one or more T cell growth factors of the present invention. In one embodiment, in a single stage of in vitro expansion of the present invention, the TIL of the present invention can be contacted with one or more T cell growth factors of the present invention first, for example, 2 hours to 48 hours in advance, for example, 2 hours in advance, 4 hours in advance, 8 hours in advance, 12 hours in advance, 24 hours in advance, or 48 hours in advance, etc., and then the expression of at least one cytokine of the TIL is increased and / or the activity is enhanced.
[0181] For example, in the first stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TIL can be increased and / or the activity is enhanced and the TIL is contacted with a T cell growth factor at substantially the same time. For example, in the second stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TIL can be increased and / or the activity is enhanced and the TIL is contacted with a T cell growth factor at substantially the same time. For example, in the third stage of in vitro expansion of the present invention, the expression of at least one cytokine of the TIL can be increased and / or the activity is enhanced and the TIL is contacted with a T cell growth factor at substantially the same time.
[0182] In one embodiment, the T cell growth factor of the present invention can be selected from one or more of the following groups: IL-2, IL-7, IL-12, IL-15, IL-21, interferon-gamma, and functionally active fragments thereof. In one embodiment, the T cell growth factor of the present invention can comprise IL-2 and / or functionally active fragments thereof. For example, the functionally active fragment of IL-2 can comprise a fragment of IL-2 known in the art that can bind to the IL-2 receptor of T cells.
[0183] In one embodiment, contacting the TILs of the present invention with one or more T cell growth factors of the present invention can comprise adding the T cell growth factors of the present invention to the cell culture medium of the TILs of the present invention. In one embodiment, the initial concentration of the T cell growth factors of the present invention in the cell culture medium of the TILs of the present invention can be at least about 300 IU / mL. In one embodiment, the initial concentration of the IL-2 of the invention in the cell culture medium of the TIL of the invention can be at least about 350 IU / mL to about 9000 IU / mL, for example, at least about 350 IU / mL, at least about 400 IU / mL, at least about 500 IU / mL, at least about 600 IU / mL, at least about 700 IU / mL, at least about 800 IU / mL, at least about 900 IU / mL, at least about 1000 IU / mL, at least about 1100 IU / mL, at least about 1200 IU / mL, at least about 1300 IU / mL, at least about 1400 IU / mL, at least about 1500 IU / mL, at least about 2000 IU / mL, at least about 2100 IU / mL, at least about 2200 IU / mL, at least about 2300 IU / mL, at least about 2400 IU / mL, In some embodiments, the present invention provides an iodine-containing pharmaceutical composition having an initial concentration of at least about 100 IU / mL, an initial concentration of at least about 100 IU / mL, an initial concentration of at least about 150 IU / mL, an initial concentration of at least about 200 IU / mL, an initial concentration of at least about 2500 IU / mL, an initial concentration of at least about 2600 IU / mL, an initial concentration of at least about 2700 IU / mL, an initial concentration of at least about 2800 IU / mL, an initial concentration of at least about 2900 IU / mL, an initial concentration of at least about 3000 IU / mL, an initial concentration of at least about 3100 IU / mL, an initial concentration of at least about 3200 IU / mL, an initial concentration of at least about 3300 IU / mL, an initial concentration of at least about 3400 IU / mL, an initial concentration of at least about 3500 IU / mL, an initial concentration of at least about 4000 IU / mL, an initial concentration of at least about 4500 IU / mL, an initial concentration of at least about 5000 IU / mL, an initial concentration of at least about 5500 IU / mL, an initial concentration of at least about 6000 IU / mL, an initial concentration of at least about 6500 IU / mL, an initial concentration of at least about 7000 IU / mL, an initial concentration of at least about 7500 IU / mL, an initial concentration of at least about 8000 IU / mL, an initial concentration of at least about 8500 IU / mL, or an initial concentration of at least about 9000 IU / mL.
[0184] For example, in the present invention, the tumor tissue-derived TIL population is selected from the following group: a TIL population derived from tumor tissue fragments, a TIL population derived from lymph node metastasis fragments, a TIL population derived from pleural effusion, a TIL population derived from peritoneal effusion, a TIL population derived from tumor resection, a TIL population derived from biopsy, and a TIL population derived from cryopreservation and resuscitation. For example, the acquisition means of the present invention may include surgical resection, puncture biopsy, core biopsy, small biopsy, or a means for obtaining a sample containing a mixture of tumor and TIL cells.
[0185] For example, in the present invention, the volume of the fragment is about 1 cubic millimeter to about 27 cubic millimeters. In one embodiment, the volume of the tumor fragment of the present invention is about 1 cubic millimeter, about 2 cubic millimeters, about 3 cubic millimeters, about 4 cubic millimeters, about 5 cubic millimeters, about 6 cubic millimeters, about 7 cubic millimeters, about 8 cubic millimeters, about 9 cubic millimeters, about 10 cubic millimeters, about 11 cubic millimeters, about 12 cubic millimeters, about 13 cubic millimeters, about 14 cubic millimeters, about 15 cubic millimeters, about 16 cubic millimeters, about 17 cubic millimeters, about 18 cubic millimeters, about 19 cubic millimeters, about 20 cubic millimeters, about 21 cubic millimeters, about 22 cubic millimeters, about 23 cubic millimeters, about 24 cubic millimeters, about 25 cubic millimeters, about 26 cubic millimeters, or about 27 cubic millimeters. For example, tumor fragments can be obtained by cutting and / or dissociating by chemical or enzymatic methods.
[0186] For example, in the present invention, the tumor is a solid tumor. For example, in the present invention, the tumor is selected from one or more of the following groups: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and kidney cancer.
[0187] In another aspect, the present invention provides a method for culturing tumor-infiltrating lymphocytes (TILs), which may comprise: (A) contacting a first population of TILs derived from tumor tissue and not expanded in vitro with IL-2, wherein the initial concentration of IL-2 in the cell culture medium of the TILs may be at least about 300 IU / mL; wherein a second population of TILs is obtained by step (A); (B) contacting the second population of TILs with IL-2, wherein the initial concentration of IL-2 in the cell culture medium of the TILs may be at least about 300 IU / mL, and then contacting the second population of TILs with, or simultaneously contacting the second population of TILs with, a nanomatrix comprising a CD3 antibody and a CD28 antibody, wherein the diameter of the nanomatrix may be from about 1 nm to about 500 nm, and each mg of the nanomatrix may comprise CD3, CD28, and IL-2, respectively. About 25 μg of each of the antibody and the CD28 antibody can be added to the cell culture medium of the TIL at a ratio of the nanomatrix to the TIL of about 1:100 to about 1:2000, so that the proportion of TIL cells expressing IL-15 in the TIL is increased by at least 5%, and the TIL is co-cultured with feeder cells, which can include peripheral mononuclear cells. The feeder cells can be added to the cell culture medium of the TIL at a ratio of the feeder cells to the TIL of about 40:1 to about 400:1; wherein, a third TIL population is obtained through step (B).
[0188] On the other hand, the present invention provides a method for culturing tumor infiltrating lymphocytes (TIL). The method for obtaining TIL cells from a subject's tissue sample can be to obtain an in situ tumor sample or a metastatic tumor sample from a patient during surgery, the weight of which can be at least about 1 g, or multiple pieces of tissue can be combined. The tumor tissue is transported at about 2-8°C in a sample transport fluid, such as a commercially available tumor tissue transport fluid, tumor tissue preservation fluid, or tumor tissue transport fluid, and processed within 48 hours. The tissue blocks can be mechanically broken into pieces of about 1-27 cubic millimeters in size, transferred into a breathable culture bag or Grex, and cultured for about 3-14 days with the addition of T cell serum-free culture medium and IL-2 at a concentration of 300-9000 IU / mL (for example, 1000-9000 IU / mL, for example, 6000 IU / mL). The harvested TIL cells can be frozen and then revived, or the cells in the culture medium can be directly collected and transferred into a breathable culture bag, or Grex, or Xuri equipment. The T cell serum-free culture medium can be added with CD28 antibodies, CD3 antibodies, and CD28 antibodies of the present invention, magnetic beads (e.g., Dynabeads) comprising CD3 antibodies and CD28 antibodies, and / or nanomatrix (e.g., transACT) comprising CD3 antibodies and CD28 antibodies, IL-2 at a concentration of 300-9000 IU / mL (e.g., 1000-9000 IU / mL, e.g., 6000 IU / mL), and transduced with a retrovirus carrying IL-15 to increase the proportion of TIL cells expressing IL-15 in the TIL by at least 5%. After activating the TIL of the present invention for a certain period of time, irradiated PBMCs (TIL and PBMCs at a ratio of about 1:40-about 1:400) are added and cultured for about 3-14 days. Cells in the culture medium can be collected using a cell processing system, washed and frozen, and detected. The final product can have a CD3 ratio greater than 80%, a cell viability greater than 50%, and greater than 80% of the T cells can be memory effector T cells and effector T cells. Upon stimulation, they can secrete IFN-γ and / or have an increased proportion of activated T cells.
[0189] In one aspect, the present invention provides tumor infiltrating lymphocytes (TILs), which can be cultured according to the culture method of the present invention. In one embodiment, the TILs provided by the present invention may comprise one or a batch of TILs cultured according to the culture method of the present invention. In one embodiment, the TILs provided by the present invention may comprise multiple or multiple batches of TILs cultured according to the culture method of the present invention and combined in any proportion.
[0190] Therapeutic dosage
[0191] For example, TILs amplified using the method of the present invention can be administered to a patient as a pharmaceutical composition. For example, the pharmaceutical composition can be a suspension of TILs in a sterile buffer. TILs amplified using the PBMCs of the present invention can be administered by any suitable route known in the art. For example, T cells can be administered with a single intra-arterial or intravenous infusion, and the infusion can last for about 30 to 60 minutes. Other suitable routes of administration can include intraperitoneal, intrathecal, and intralymphatic administration. For example, affecting tumor growth can comprise a reduction in the volume of the tumor to about 99% to about 0.1% of the volume prior to administration, e.g., about 99%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2% or about 0.1%.
[0192] For example, any suitable dose of TILs can be administered. For example, when the tumor is a melanoma, about 1×10 9 to about 13.7×10 10 For example, approximately 1×10 9 to about 12×10 10 For example, approximately 1.2 × 10 10 to about 4.3×10 10 For example, approximately 3 × 10 10 to about 12×10 10 For example, approximately 4 × 10 10 to about 10×10 10 For example, approximately 5 × 10 10 to about 8×10 10 For example, approximately 6 × 10 10 to about 8×10 10 For example, approximately 7 × 10 10 to about 8×10 10 For example, a therapeutically effective dose may be about 1×10 9 to about 13.7×10 10 , preferably 2.3×10 9 to about 13.7×10 10 For example, a therapeutically effective dose may be about 1×10 9 to about 12×10 10 For example, a therapeutically effective dose can be about 1.2×10 10to about 4.3×10 10 For example, a therapeutically effective dose can be about 3×10 10 to about 12×10 10 For example, a therapeutically effective dose can be about 4×10 10 to about 10×10 10 For example, a therapeutically effective dose can be about 5×10 10 to about 8×10 10 For example, a therapeutically effective dose can be about 6×10 10 to about 8×10 10 For example, a therapeutically effective dose can be about 7×10 10 to about 8×10 10 TIL.
[0193] For example, the number of TILs provided in the composition of the present invention may be about 1×10 6 to about 9×10 13 , for example, about 1×10 6 , about 2×10 6 , about 3×10 6 , about 4×10 6 , about 5×10 6 , about 6×10 6 , about 7×10 6 , about 8×10 6 , about 9×10 6 , about 1×10 7 , about 2×10 7 , about 3×10 7 , about 4×10 7 , about 5×10 7 , about 6×10 7 , about 7×10 7 , about 8×10 7 , about 9×10 7 , about 1×10 8 , about 2×10 8 , about 3×10 8 , about 4×10 8 , about 5×10 8 , about 6×10 8 , about 7×10 8 , about 8×10 8 , about 9×10 8 , about 1×10 9 , about 2×10 9 , about 3×10 9 , about 4×10 9 , about 5×10 9 , about 6×109 , about 7×10 9 , about 8×10 9 , about 9×10 9 , about 1×10 10 , about 2×10 10 , about 3×10 10 , about 4×10 10 , about 5×10 10 , about 6×10 10 , about 7×10 10 , about 8×10 10 , about 9×10 10 , about 1×10 11 , about 2×10 11 , about 3×10 11 , about 4×10 11 , about 5×10 11 , about 6×10 11 , about 7×10 11 , about 8×10 11 , about 9×10 11 , about 1×10 12 , about 2×10 12 , about 3×10 12 , about 4×10 12 , about 5×10 12 , about 6×10 12 , about 7×10 12 , about 8×10 12 , about 9×10 12 , about 1×10 13 , about 2×10 13 , about 3×10 13 , about 4×10 13 , about 5×10 13 , about 6×10 13 , about 7×10 13 , about 8×10 13 , or about 9×10 13 For example, the number of TILs provided in the compositions of the present invention may range from about 1×10 6 to 5×10 6 , about 5×10 6 to 1×10 7 , about 1×10 7 to 5×10 7 , about 5×10 7 to 1×10 8 , about 1×10 8 to 5×10 8 , about 5×10 8 to 1×10 9, about 1×10 9 to 5×10 9 , about 5×10 9 to 1×10 10 , about 1×10 10 to 5×10 10 , about 5×10 10 to 1×10 11 , about 5×10 11 to 1×10 12 , about 1×10 12 to 5×10 12 , about 5×10 12 to 1×10 13 , about 1×10 13 to 5×10 13 , or about 5 × 10 13 to 9×10 13 .
[0194] For example, the concentration of TILs provided in the compositions of the present invention can be less than 100% to about 0.0001% of the composition, for example, about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19%, about 18%, about 17%, about 16%, about 15%, about 14%, about 13%, about 12%, about 11%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, about 0.1%, about 0.09%, about 0.0 0.004%, about 0.003%, about 0.002%, about 0.001%, about 0.0009%, about 0.008%, about 0.007%, about 0.006%, about 0.005%, about 0.004%, about 0.003%, about 0.002%, about 0.001%, about 0.0009%, about 0.0008%, about 0.0007%, about 0.0006%, about 0.0005%, about 0.0004%, about 0.0003%, about 0.0002%, or about 0.0001% w / w, w / v, or v / v.
[0195] For example, the concentration of TILs provided in the compositions of the present invention can be greater than about 90% to about 0.0001% of the composition, e.g., about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 19.75%, about 19.50%, about 19.25%, about 19%, about 18.75%, about 18.50%, about 18.25%, about 18%, about 17.75%, about 17.50%, about 17.25%, about 17%, about 16.75%, about 16.50%, about 16.25%, about 16%, about 15.75%, about 15.50%, about 16.25%, about 16%. %, about 15.25%, about 15%, about 14.75%, about 14.50%, about 14.25%, about 14%, about 13.75%, about 13.50%, about 13.25%, about 13%, about 12.75%, about 12.50%, about 12.25%, about 12%, about 11.75%, about 11.50%, about 11.25%, about 11%, about 10.75%, about 10.50%, about 10.25%, about 10%, about 9.75%, about 9.50%, about 9.25%, about 9%, about 8.75%, about 8.50%, about 8.25%, about 8%, about 7.75 %, about 7.50%, about 7.25%, about 7%, about 6.75%, about 6.50%, about 6.25%, about 6%, about 5.75%, about 5.50%, about 5.25%, about 5%, about 4.75%, about 4.50%, about 4.25%, about 4%, about 3.75%, about 3.50%, about 3.25%, about 3%, about 2.75%, about 2.50%, about 2.25%, about 2%, about 1.75%, about 1.50%, about 1.25%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, about 0.1%, about 0.09%, about 0.08%, about 0.002%, or about 0.0001% w / w, w / v, or v / v.
[0196] For example, the concentration of TILs provided in the compositions of the present invention can range from about 0.0001% to about 50%, about 0.001% to about 40%, about 0.01% to about 30%, about 0.02% to about 29%, about 0.03% to about 28%, about 0.04% to about 27%, about 0.05% to about 26%, about 0.06% to about 25%, about 0.07% to about 24%, about 0.08% to about 26%, about 0.09% to about 27%, about 0.10% to about 28%, about 0.11% to about 29%, about 0.12% to about 29%, about 0.13% to about 29%, about 0.14% to about 29%, about 0.15% to about 29%, about 0.16% to about 29%, about 0.17% to about 29%, about 0.18% to about 29%, about 0.19% to about 29%, about 0.20% to about 29%, about 0.21% to about 29%, about 0.22% to about 29%, about 0.23% to about 29%, about 0.24% to about 29%, about 0.25% to about 29%, about 0.26% to about 29%, about 0.27% to about 29%, about 0.28% to about 29%, about 0.29% to about 29%, about 0. 0.08% to about 23%, about 0.09% to about 22%, about 0.1% to about 21%, about 0.2% to about 20%, about 0.3% to about 19%, about 0.4% to about 18%, about 0.5% to about 17%, about 0.6% to about 16%, about 0.7% to about 15%, about 0.8% to about 14%, about 0.9% to about 12%, or about 1% to about 10% w / w, w / v or v / v.
[0197] For example, the concentration of TIL provided in the compositions of the present invention can range from about 0.001% to about 10%, about 0.01% to about 5%, about 0.02% to about 4.5%, about 0.03% to about 4%, about 0.04% to about 3.5%, about 0.05% to about 3%, about 0.06% to about 2.5%, about 0.07% to about 2%, about 0.08% to about 1.5%, about 0.09% to about 1%, or about 0.1% to about 0.9% w / w, w / v, or v / v of the composition.
[0198] For example, the amount of TIL provided in the composition of the present invention can be equal to or less than about 10 g to about 0.0001 g, such as equal to or less than about 10 g, about 9.5 g, about 9.0 g, about 8.5 g, about 8.0 g, about 7.5 g, about 7.0 g, about 6.5 g, about 6.0 g, about 5.5 g, about 5.0 g, about 4.5 g, about 4.0 g, about 3.5 g, about 3.0 g, about 2.5 g, about 2.0 g, about 1.5 g, about 1.0 g, about 0.95 g, about 0.9 g, about 0.85 g, about 0.8 g, about 0.75 g, about 0.7 g, about 0.65 g, about 0.6 g, about 0.55 g, about 0.5 g, about 0.45 g, about 0.4 g, about 0.35 g, about 0. .3g, about 0.25g, about 0.2g, about 0.15g, about 0.1g, about 0.09g, about 0.08g, about 0.07g, about 0.06g, about 0.05g, about 0.04g, about 0.03g, about 0.02g, about 0.01g, about 0.009g, about 0.008g, about 0.007g, about 0.006g , about 0.005g, about 0.004g, about 0.003g, about 0.002g, about 0.001g, about 0.0009g, about 0.0008g, about 0.0007g, about 0.0006g, about 0.0005g, about 0.0004g, about 0.0003g, about 0.0002g, or about 0.0001g.
[0199] For example, the amount of TIL provided in the composition of the present invention can be greater than about 0.0001 g to about 10 g, such as about 0.0001 g, about 0.0002 g, about 0.0003 g, about 0.0004 g, about 0.0005 g, about 0.0006 g, about 0.0007 g, about 0.0008 g, about 0.0009 g, about 0.001 g, about 0.0015 g, about 0.002 g, about 0.0025 g, about 0.003 g, about 0.0035 g, about 0.004 g, about 0.0045 g, about 0.005 g, about 0.006 g, about 0.007 g, about 0.008 g, about 0.009 g, about 0.001 g, about 0.0015 g, about 0.002 g, about 0.0025 g, about 0.003 g, about 0.0035 g, about 0.004 g, about 0.0045 g, about 0.005 g, about about 0.0055g, about 0.006g, about 0.0065g, about 0.007g, about 0.0075g, about 0.008g, about 0.0085g, about 0.009g, about 0.0095g, about 0.01g, about 0.015g, about 0.02g, about 0.025g, about 0.03g, about 0.035g, about 0.04g, about 0.045g, about 0.05g, about 0.055g, about 0.06g, about 0.065g, about 0.07g, about 0.075g, about 0.08g, about 0.085g, About 0.09g, about 0.095g, about 0.1g, about 0.15g, about 0.2g, about 0.25g, about 0.3g, about 0.35g, about 0.4g, about 0.45g, about 0.5g, about 0.55g, about 0.6g, about 0.65g, about 0.7g, about 0.75g, about 0.8g, about 0.85g, about 0.9g, about 0.95g, about 1g, about 1.5g, about 2g, about 2.5g, about 3g, about 3.5g, about 4g, about 4.5g, about 5g, about 5.5g, about 6g, about 6.5g, about 7g, about 7.5g, about 8g, about 8.5g, about 9g, about 9.5g, or about 10g.
[0200] For example, TIL can be administered in a single dose. Such administration can be by injection, for example, intravenous injection. For example, TIL can be administered in multiple doses. Dosage can be from once to six times per year, for example, once, twice, three times, four times, five times, or six times per year. Dosage can be once a month, once every two weeks, once a week, or once every two days. For example, administration of TIL can be continuous.
[0201] For example, the tumor can be selected from one or more of the following groups: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and kidney cancer. For example, the tumor of the present invention can refer to an advanced solid tumor. For example, the tumor of the present invention can refer to an incurable solid tumor. For example, the tumor of the present invention can refer to a recurrent and / or metastatic solid tumor. For example, the tumor of the present invention can refer to an incurable recurrent and / or metastatic advanced solid tumor.
[0202] In one aspect, the present invention provides a method for preventing and / or treating tumors, which may comprise administering the TILs of the present invention and / or the pharmaceutical formulations of the present invention to a subject. In some embodiments, the tumor is selected from a solid tumor. In some embodiments, the tumor may be selected from one or more of the following groups: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and renal cancer. For example, the tumor of the present invention may refer to an advanced solid tumor. For example, the tumor of the present invention may refer to an incurable solid tumor. For example, the tumor of the present invention may refer to a recurrent and / or metastatic solid tumor. For example, the tumor of the present invention may refer to an incurable recurrent and / or metastatic advanced solid tumor. For example, the subject of the present invention may meet one, more, or all of the inclusion criteria of the inclusion criteria of the present invention. For example, the subject of the present invention may not have one, more, or all of the exclusion criteria of the exclusion criteria of the present invention. For example, the effect of the present invention may be evaluated by the safety, tolerability assessment, efficacy assessment, and / or pharmacodynamic and pharmacokinetic assessment described in the present invention. For example, the subject of the present invention may isolate a volume ≥0.5 cm 3 Tissue blocks (from a single lesion or a combination of multiple lesions) are used to prepare autologous tumor-infiltrating lymphocytes.
[0203] Without intending to be bound by any theory, the following examples are merely intended to illustrate the methods and uses of the present invention and are not intended to limit the scope of the present invention.
[0204] Example
[0205] Example 1 Tumor Infiltrating Lymphocyte (TIL) Cell Culture Process
[0206] 1.1 Feeder Cell Receipt and Preparation
[0207] 1.1.1 Single blood collection reception
[0208] Record the blood collection information, batch number and volume, and rewarm to room temperature.
[0209] 1.1.2 Manual Isolation and Cryopreservation of PBMCs (Peripheral Blood Mononuclear Cells)
[0210] Disinfect the blood bag with 75% alcohol and transfer it to a biosafety cabinet. After cutting the blood bag with sterile scissors, transfer the single-collected blood to a 50mL centrifuge tube. Use a 20mL syringe to inject 20mL of PBS or saline to clean the blood bag, and transfer the washing solution to a 50mL centrifuge tube. The liquid volume in each 50mL centrifuge tube should not exceed 30mL. Centrifuge the single-collected blood at 3000g for 10 minutes. During the centrifugation process, prepare 6-8 50mL centrifuge tubes and add rewarmed lymphocyte separation fluid (Tianjin Haoyang Ficoll), 20mL / tube. After centrifugation, discard the upper layer of plasma, dilute the cell pellet with PBS or saline, and slowly add the diluted blood cell mixture to the upper layer of lymphocyte separation fluid without destroying the interface. Add approximately 25mL of sample to each tube, and no more than 28mL.
[0211] Centrifuge in a swing-out rotor at 500-600g for 15-30 minutes at 18-22°C. The resulting buffy coat layer will be at the interface between saline and Ficoll, a lymphocyte separation buffer. Aspirate the upper plasma and saline layer and pipette the middle buffy coat layer into a clean 50mL centrifuge tube. Dilute the collected buffy coat layer with PBS or saline and centrifuge at 600g for 10 minutes at room temperature. After centrifugation, discard the supernatant and wash the cells once with PBS or saline, centrifuging at 500g for 5 minutes at room temperature.
[0212] If there are a large number of red blood cells, erythrocyte lysis can be performed after centrifugation. Add erythrocyte lysis buffer at a ratio of 1:2 to 1:3 based on the volume of the cell pellet, mix well, and lyse at room temperature for 10 minutes. Gently mix the centrifuge tube 2-3 times in between to ensure lysis. After lysis, wash the cells with PBS or saline. Wash the cells twice after lysis and centrifuge at 400g for 6 minutes. Sample and count before the final centrifugation.
[0213] Discard the supernatant and resuspend the cells in basal medium to adjust the cell density to about 2-3×10 7 cells / mL, the liquid level can be no more than 1 cm, and the volume of each T225 culture flask can be less than 200 mL; in the flat state, X-ray irradiation 50 Gy. Centrifuge and discard the supernatant. Cryopreserve the cells according to the counting results, about 1-2×10 8 cells / mL, 1-2 mL / vial; place the cells in a programmed cooling box and transfer to a -80℃ refrigerator for freezing.
[0214] 1.1.3 Automated PBMC Isolation and Cryopreservation
[0215] Aseptically connect the blood bag tubing to the input end of the cpro separation kit (Cytiva). If the blood volume is greater than 120mL, a pre-concentration step is performed to concentrate the blood volume to less than 120mL. The neatcell program can be used for PBMC separation and washing. The washing solution is normal saline, and the intermediate volume is 20mL; the resuspension solution is basal culture medium, and 80mL is added per batch. After separation, each donor's PBMC is a bag of 100mL. In the flat state, the liquid level can not exceed 1 cm, and the X-ray irradiation is 50Gy. After irradiation, samples are taken and counted, and the cells are collected and washed three times using the culture wash program. The washing solution is normal saline; the intermediate volume and final volume are set so that every 1×10 9 cells in no less than 2 mL; add an equal amount of 2x freezing solution and mix well. Use 1x freezing solution to adjust the cell density to about 1×10 7 cells / mL to 2×10 8 cells / mL, dispensed into 20 mL / bag, cryopreserved in a programmed cooling apparatus, and stored in liquid nitrogen.
[0216] 1.2 Tumor tissue receipt and processing
[0217] 1.2.1 Organization reception
[0218] Receive tumor tissue and blood samples from donors, verify and record sample information, and print corresponding sample labels.
[0219] 1.2.2 Tissue processing and culture
[0220] Disinfect the sample tube and blood collection tube with 75% alcohol and transfer them to a biosafety cabinet. Isolate PBMC cells from the blood sample and cryopreserve according to the above-mentioned PBMC manual isolation and freezing procedures. Take a culture flask or culture bag with a breathable surface, such as a culture bag (Origen), and add 300 mL of thawed complete culture medium. The complete culture medium can be any X-vivo15 medium or other commercial T cell culture medium, such as Stem Cell, Lonza, Thermo, Miltenyi, etc., and can be supplemented with essential amino acids and antibiotics, and IL-2 at a concentration of 300-9000 IU / mL (for example, 1000-9000 IU / mL, for example, 6000 IU / mL). Take several 10 cm culture dishes, add an appropriate amount of culture medium, use sterile ophthalmic forceps to remove the tumor tissue from the sample tube and place it in a 10 cm culture dish. The amount of culture medium should just cover the tumor tissue. Observe the tissue morphology and record it. Wash the tissue and change the culture dish. Use ophthalmic scissors and forceps to perform initial shearing, removing adipose and necrotic tissue. Each tissue block is then minced to approximately 27 cubic millimeters. A non-suspended tumor tissue block is obtained. A 20 mL syringe is used to remove the internal stopcock and connect to a culture bag. Using a pipette, approximately 1 g of tissue is transferred from the syringe into the culture bag. The culture bag is placed in a CO2 incubator for incubation. The scissors and forceps are cleaned and initially disinfected with 75% alcohol. After ultrasonic cleaning, they are sterilized to obtain the first TIL population.
[0221] 1.3 Step (A) In vitro expansion and harvesting
[0222] 1.3.1 Step (A) In vitro amplification
[0223] Depending on the cell growth status, the medium should be replenished or half-replaced every 3-7 days to ensure cell nutrition. Complete culture medium can be arbitrarily selected from X-vivo 15 culture medium or other commercial T cell culture medium, such as T cell culture medium of brands such as Stem Cell, Lonza, Thermo, and Miltenyi Biopharmaceuticals. Essential amino acids and antibiotics can be added, and IL-2 (Double Heron) at a concentration of 300-9000 IU / mL (for example, 1000-9000 IU / mL, for example, 6000 IU / mL) can be added. Samples can be taken and counted on the 3rd to 14th day of step (A). If the cell number is between 5×10 5 to 5×10 8 During this time, the harvesting step (A) is entered.
[0224] 1.3.2 Results of Step (A)
[0225] Collect the cells after in vitro expansion in step (A), centrifuge, discard the culture medium, wash the cells once with PBS or normal saline, obtain the TILs (second TIL population) expanded in vitro in step (A), and take samples for counting and retain about 5×10 5 to 2×10 8 cells into the subsequent in vitro expansion step; about 5×10 5 The remaining cells can be added to the cryopreservation medium and cryopreserved as cryopreserved preREP TIL in vitro cells.
[0226] 1.4 Step (B) TIL activation
[0227] Continue to culture the TILs (second TIL population) expanded in vitro in step (A), or recover the frozen preREP TIL cells in vitro and perform TIL activation in step (B).
[0228] Complete culture medium can be selected from X-vivo 15 medium or other commercial T cell culture medium, such as Stem Cell, Lonza, Thermo, Miltenyi Biotech, etc. Essential amino acids and antibiotics can be added to adjust the cell density to 5×10 5 to 2×10 6 Cells are suspended in a 24-well culture plate at 1 mL / well and IL-2 is added at a concentration of 300-9000 IU / mL (e.g., 1000-9000 IU / mL, or 6000 IU / mL). T cell activators, such as CD3 agonists and / or CD28 agonists, can be added to the culture medium of each TIL population, for example, approximately 30 ng / mL of CD3 antibody (Miltenyi Biotech, OKT3), approximately 30 ng / mL of CD28 antibody (Merck, 15E8), magnetic beads (Dynabeads, approximately 1 to 10 μm diameter, Thermo Fisher) at a ratio of approximately 1:2 to 2:1 beads to TILs, and / or transACT (approximately 100 to 500 nm diameter, Miltenyi) at a ratio of approximately 1:100 to 1:2000 transACT to TILs. Culture is continued for approximately 0-4 days to obtain a third TIL population.
[0229] 1.5 Step (C) TIL cell transduction
[0230] One day before transduction, coat a 24-well suspension culture plate with recombinant human fibrin fragment (Retronectin, Takara) at a final concentration of 15 μg / mL, with 250 μL per well. Protect from light and incubate at 4°C overnight. Remove the coated 24-well plate, discard the coating solution, and add 500 μL of blocking solution containing 2% BSA and block at room temperature for 30 minutes. Discard the blocking solution and wash the plate twice with 500 μL / well of a plate wash solution containing 2.5% HEPES, then discard the wash solution. The experimental group was transduced with a retrovirus carrying IL-15 (the amino acid sequence can be shown as SEQ ID NO: 1), while the GFP control group was transduced with a retrovirus carrying GFP.
[0231] To construct a retroviral plasmid carrying IL-15, the IL-15 gene fragment of the present invention can be synthesized, digested with EcoRI and NotI, and the exogenous IL-15 fragment recovered. Plasmid MP71 is then digested with EcoRI and NotI to recover the vector fragment. The exogenous fragment and the vector fragment are then ligated using T4 Ligase to produce a retroviral plasmid carrying IL-15. A similar method can be used to construct a retroviral plasmid carrying GFP.
[0232] Add 0.25-2 mL of retroviral solution to each well and centrifuge at 32°C, 2000 g for 2 hours. No cell transduction was performed on the negative control group. Discard the supernatant from the 24-well plate and add the third TIL group to each well of the 24-well plate in a volume of 300-500 μL. The cell concentration was approximately 1×10 6 Cells / mL. Centrifuge at 1000g for 10 minutes at 30-32°C. After centrifugation, place the culture plate in a 37°C, 5% CO2 incubator to obtain transduced cells. Culture for approximately 0-4 days after transduction to obtain the fourth TIL population.
[0233] 1.6 Step (D) TIL cell culture after transduction
[0234] Feeder cells are added to the fourth TIL cell group for culture. The time for contacting TIL with feeder cells needs to be a certain time T after the TIL is contacted with IL-2 and T cell activator in step (B). n Afterwards (T n The time period can be from 0 hours to 12 days, for example, 24 hours or 48 hours). First, resuscitate the mixed feeder cells from 1-5 donors; mix the activated TIL cells and feeder cells at a ratio of approximately 1:200, transfer them to a G-Rex100 culture flask or breathable bag, and supplement with complete culture medium. Samples are taken and counted every 1-3 days, and the medium is replenished or half-filled according to the cell status until the total number of cells is greater than 1×10 9 Alternatively, the in vitro expansion culture of step (D) is carried out for about 5 days to about 14 days, and the in vitro expansion culture of step (D) is terminated.
[0235] 1.7 Harvesting of Tumor-Infiltrating Lymphocytes
[0236] Take the cells amplified in step (D), centrifuge and discard the culture supernatant, and wash three times with PBS or saline or compound electrolyte solution to obtain TILs amplified in step (D) (fifth TIL population). Samples are counted during the third wash. According to the counting results, after the final centrifugation, discard the supernatant and take 3×10 6 The cells were sent for quality control testing; all the remaining cells were added to the freezing solution and the cell density was adjusted to 1-3×10 8 cells / mL for cryopreservation.
[0237] Example 2 Detection of transduction efficiency of TIL cells
[0238] Starting from the 14th day after transduction, the transduction efficiency of the TIL cells of the present invention was detected by flow cytometry (Beckman CouLter) every 3 days.
[0239] Figure 1 shows that for TIL cells from donor A, the CD4 + IL-15 transduction efficiency of cells;
[0240] Figure 2 shows that for TIL cells from donor A, the CD8 + The results showed that the IL-15 of the present invention can achieve a high transduction efficiency in TIL cells, and the transduction efficiency of IL-15 continues to increase.
[0241] Example 3 Detection of the expansion efficiency and viability of TIL cells
[0242] IL-2 is an important factor regulating T cell growth. This example tests whether the IL-15-transduced TIL cells of the present invention can survive and / or proliferate independently of IL-2.
[0243] Starting on day 8 after transduction, TIL cells in each group were re-plated with the same total number of cells and cultured in a cell culture medium without IL-2, i.e., cultured without IL-2. The expansion efficiency and viability of TIL cells were analyzed every 3 days using a cell counter. The expansion efficiency was expressed as a standardized expansion rate: the total number of cells on the day of IL-2 withdrawal (day 0) was taken as 100%, and the standardized expansion rate on day n was the total number of cells on day n / the total number of cells on day 0 × 100%. The viability represents the percentage of surviving cells to the total number of cells.
[0244] Figure 3 shows the standardized expansion rate of TIL cells in each group for TIL cells derived from donor B;
[0245] Figure 4 shows the viability of TIL cells in each group for TIL cells derived from donor B. The results show that even when IL-2 is withdrawn, the IL-15-transduced TIL cells of the present invention can still have significant expansion capacity and maintain a high cell viability.
[0246] Example 4 Detection of TIL cell expansion
[0247] Starting from the 8th day after transduction, TIL cells in each group were re-plated with the same total number of cells, and the expansion was detected 3 days later.
[0248] According to the instructions for the CTG kit (CellTiter-Glo Luminescent Cell Viability Assay, Promega), mix the CTG substrate (CellTiter-Glo Substrate) and CTG buffer (CellTiter-Glo Buffer) to prepare the CTG reaction solution. Add 50 μL of the test cell suspension to a 96-well microplate, setting wells containing only culture medium as the background fluorescence value. Add an equal volume of CTG reaction solution to each well, shake on a horizontal shaker for 2 minutes, and let it stand at room temperature for 10 minutes to allow the fluorescence signal to stabilize before reading the fluorescence value.
[0249] Figure 5 shows the proliferation capacity of TIL cells from donor C in each group. *** indicates p < 0.001. The results demonstrate that TIL cells transduced with IL-15 have significant expansion capacity.
[0250] Example 5 Detection of cytokine secretion by TIL cells
[0251] Starting on day 8 after transduction, TIL cells from each group were re-plated with the same total number of cells and stimulated with CD3 antibody (Tongli Haiyuan). Supernatants were collected 24 hours later for cytokine secretion assays.
[0252] Cytokine secretion assays can be performed according to the instructions for the BD Cytokine Assay Kit. Reconstitute the lyophilized human Th1 / Th2 / Th17 cytokine standard powder (BD) with 2 mL of Assay Diluent (BD) (the standard stock solution contains 5000 pg / mL of each cytokine). Then, serially dilute the standard solution in the following order: 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 1:512, and 1:1024. Label the tube "Standard Tube." Use one tube containing only Assay Diluent as a reference. Add 2 μL / Beads / well of each Capture Beads (BD), then add 10 μL / well of PE Detection Reagent (BD) and mix to prepare a mixture. Add 22 μL / well to a V-bottom 96-well plate, then add 10 μL / well of the supernatant of each standard and experimental group and mix. Incubate at room temperature for 3 hours in the dark.
[0253] At the end of incubation, add 200 μL Wash Buffer (BD) to each well and centrifuge at 500 g for 3 minutes. After centrifugation, add 100 μL Wash Buffer (BD) to each well and resuspend the cells for flow cytometry analysis.
[0254] Figures 6, 7, and 8 show the secretion of IL-2, IFN-γ, and IL-10, respectively, by TIL cells from donor D after stimulation with CD3 antibodies. *** indicates p < 0.001, and ** indicates p < 0.01. These results demonstrate that IL-15-transduced TIL cells exhibit significantly greater cytokine secretion after CD3 antibody stimulation.
[0255] Starting on day 8 after transduction, TIL cells from each group were replated at the same total cell count and stimulated with transACT (a nanomaterial containing antibodies to CD3 and CD28, manufactured by Miltenyi). Supernatants were collected 24 hours later for cytokine secretion analysis.
[0256] Figures 9 and 10 show, respectively, the secretion of TNF-α and IL-10 by TIL cells from donor E following transACT stimulation. ** indicates p < 0.01, and * indicates p < 0.05. These results demonstrate that IL-15-transduced TIL cells exhibit significantly greater cytokine secretion following CD28 antibody stimulation.
[0257] Starting on day 8 after transduction, TIL cells from each group were re-plated with the same total number of cells without stimulation. 24 hours later, supernatants were collected for cytokine secretion assays.
[0258] Figures 11 and 12 show, respectively, the secretion of IFN-γ and IL-2 by TIL cells from donor F in each group. **** indicates p < 0.0001, and ** indicates p < 0.01. These results demonstrate that TIL cells transduced with IL-15 exhibit significantly greater cytokine secretion.
[0259] Starting on day 8 after transduction, TIL cells from each group were re-plated with the same total cell number and cultured in IL-2-free medium. Supernatants were collected on day 15 after culture without IL-2 for cytokine secretion analysis.
[0260] Figures 13 and 14 show, respectively, the secretion of IFN-γ and IL-6 by TIL cells from donor G in each group after IL-2 withdrawal. ** indicates p < 0.01, and * indicates p < 0.05. These results demonstrate that IL-15-transduced TIL cells exhibit significantly greater cytokine secretion in the absence of IL-2.
[0261] Example 6 TIL cell killing ability detection
[0262] Starting from the 7th day after transduction, A375 tumor cells were cultured at 2×10 4 The next day, each group of TIL cells were co-cultured with the above-mentioned A375 cells at an effector-target ratio (TIL cells: tumor cells) of 0.3:1 or 1:1.
[0263] According to the instructions of the apoptosis detection reagent (Incucyte Caspase-3 / 7 Green Dye for Apoptosis, Sartorius), 0.2 μL / well was added. Caspase-3 / 7 Green Dye for Apoptosis was added, and 25 μL of culture medium was added per well to dilute Caspase 3 / 7 Green Dye. Caspase 3 / 7 activity was recorded using an Incucyte recorder (Sartorius) every 3 hours for approximately 5 days to analyze the ability of TILs to kill tumor cells.
[0264] FIG15 shows the cytotoxicity test results of TIL cells derived from donor H when co-cultured with tumor cells at an effector-target ratio of 0.3:1. **** indicates p<0.0001.
[0265] Figure 16 shows the cytotoxicity of TIL cells derived from donor H, co-cultured with tumor cells at a 1:1 effector-to-target ratio. **** indicates p < 0.0001. These results demonstrate that IL-15-transduced TIL cells exhibit significantly greater cytotoxicity.
[0266] At 24 hours after co-culture, the supernatant was collected for cytokine secretion detection.
[0267] Figure 17 shows the results of IL-2 secretion by TIL cells from donor H co-cultured with tumor cells at an effector-target ratio of 0.3:1 or 1:1. *** indicates p < 0.001, **** indicates p < 0.0001.
[0268] Figure 18 shows the IFN-γ secretion by TIL cells from donor H co-cultured with tumor cells at an effector-to-target ratio of 0.3:1 or 1:1. * indicates p < 0.05. These results demonstrate that IL-15-transduced TIL cells exhibit significantly enhanced cytokine secretion when exposed to tumor cells.
[0269] Example 7 Detection of TCR Clonal Diversity of TIL Cells
[0270] Starting on day 8 after transduction, TIL cells in each group were re-plated with the same total number of cells and cultured in a medium without IL-2. T cell receptor (TCR) clonal diversity in TIL was analyzed on days 8 and 26 after transduction.
[0271] According to the instructions of the TCR repertoire kit (Beta Mark TCR VβRepertoire Kit, Beckman Coulter), 4 μL of Beta Mark TCR VβRepertoire Kit Tube AH antibodies were added to each of the 8 tubes A to H. 1 μL of BV510-labeled CD3 antibody (BD), 1 μL of PerCP-cy5.5-labeled CD8 antibody (BD), 1 μL of PE-cy7-labeled CD4 antibody (BD), and 0.01 μL of eFluor780-labeled dead cell dye (eBioscience) were added to each tube. The cells to be tested were divided into 8 parts and added to tubes A to H respectively, mixed well, and incubated at 4°C for 30 minutes. After staining, centrifuge and discard the supernatant. Resuspend and wash once with PBS for flow cytometry detection.
[0272] TCR diversity of TIL cells was identified according to the instructions of the TCR repertoire kit (Beta Mark TCR Vβ Repertoire Kit, Beckman Coulter). Table 1 shows the corresponding relationship between the fluorescence of tubes A to H and the TCR Vβ clones.
[0273] Table 1 Correspondence between the fluorescence of tubes A to H and TCR Vβ clones
[0274] Table 2 and Figure 19 show that for TIL cells from donor 1, the CD8 + Diversity of T cell TCR Vβ clones.
[0275] Table 2 CD8 on day 8 after transduction + Diversity of T cell TCR Vβ clones
[0276] Table 3 and Figure 20 show that for TIL cells from donor 1, the CD8 + Diversity of T cell TCR Vβ clones. Wherein the TCR Vβ clone is "other", it can mean that the T cells at this ratio do not have TCR Vβ that can be identified by the TCR repertoire kit.
[0277] Table 3 CD8 on day 26 after transduction + Diversity of T cell TCR Vβ clones
[0278] Table 4 and Figure 21 show that for TIL cells from donor 1, the CD4 + Diversity of T cell TCR Vβ clones.
[0279] Table 4 CD4 on day 8 after transduction + Diversity of T cell TCR Vβ clones
[0280] Table 5 and Figure 22 show that for TIL cells from donor 1, the CD4 + Diversity of T cell TCR Vβ clones. Wherein the TCR Vβ clone is "other", it can mean that the T cells at this ratio do not have TCR Vβ that can be identified by the TCR repertoire kit.
[0281] Table 5 CD4 on day 26 after transduction + Diversity of T cell TCR Vβ clones
[0282] The results showed that on day 26, the CD8 + T cell Vβ18, Vβ7.2, Vβ11, Vβ5.2, Vβ16, Vβ3, Vβ20, Vβ23, Vβ13.1, Vβ4, Vβ22, Vβ21.3, Vβ17, Vβ5.1, Vβ5.3 and Vβ2 disappear, CD4 + The disappearance of T cell Vβ7.2, Vβ5.2, Vβ11, Vβ16 and Vβ20 means a decrease in TCR clone diversity; TIL cells transduced with IL-15 can maintain more β chain subtypes and can significantly maintain the diversity of TCR clones for a long time, which can help achieve stronger antigen recognition and immune response capabilities for tumor cells.
[0283] Example 8 Detection of the persistence and distribution of TIL cells in vivo
[0284] Immunodeficient mice (NOG mice, Weitonglihua, strain code 408) were subcutaneously inoculated with A375 cells at a number of approximately 1×10 6 cells / mouse. 7 days after inoculation, when the tumor volume reaches 50-80mm 3 The mice were randomly divided into groups according to the tumor size (as shown in Table 6).
[0285] Table 6 Grouping
[0286] Each group was injected with TIL from donor J (TIL not transduced with IL-15, TIL not transduced with IL-15 + IL-2, TIL transduced with IL-15, and an equal volume of PBS as a blank control) by tail vein at a dose of 5×10 6cells / mouse, and the day of TIL cell injection was designated as day 0. For control group 2, IL-2 was injected intraperitoneally once every 12 hours for 6 consecutive times. The injection dose of IL-2 was 1×10 5 IU / time. On days 6 and 21 after TIL cell injection, tumors, spleen, bone marrow, lung tissue, and blood (anticoagulant treatment) were removed from the mice, and the number of T cells and their dynamic distribution in tissues were analyzed by flow cytometry.
[0287] Figures 23, 24, 25, 26, and 27 show the number of T cells in various tissues on day 6 and day 21 after TIL cell injection, respectively. The results indicate that IL-15-transduced TIL cells can have a longer in vivo persistence and, in tumor tissue sites, have stronger infiltration and / or expansion capabilities.
[0288] Example 9 Clinical Effect Detection of TIL Cells
[0289] Safety and effectiveness of tumor-infiltrating lymphocytes of the present invention
[0290] Before administering TIL to a subject, the subject's immune system may be treated, for example, cyclophosphamide and / or fludarabine may be administered to the subject 4 to 2 days before administering TIL obtained by the culture method to the subject. For example, at a dose of about 300 to 500 mg / m 2 Cyclophosphamide was administered at a dose of 20 to 30 mg / m 2 Fludarabine was administered at a dose of 1 mg / day.
[0291] The TIL of the present invention can be used at a rate of 5×10 9 to 5×10 10 The number of cells was administered intravenously to the subject once. 12±4 hours after the infusion of the IL-15-overexpressing TIL of the present invention, human recombinant interleukin-2 (IL-2) was first intravenously injected, and then IL-2 was intravenously injected every 12±4 hours. The first two doses of IL-2 were 3×10 5 IU / kg / time, after which the researcher and the sponsor's medical monitor will comprehensively determine the risks and benefits based on the subject's clinical reality, and IL-2 can be maintained at 3×10 5 IU / kg / time or adjust the dose to 1.5×10 5 IU / Kg, or skip the next bolus, or terminate the bolus, up to 10 injections within 5 days to support the survival of autologous tumor-infiltrating lymphocytes in the body and ensure the safety of the subjects.
[0292] For the tumor infiltrating lymphocyte (TIL) treatment regimen of the present invention, the efficacy and safety of tumor patients are evaluated.
[0293] Inclusion criteria
[0294] Exclusion criteria
[0295] Clinical evaluation plan:
[0296] Clinical data show that the transduced cell therapy of the present invention achieved complete or partial remission in patients with malignant melanoma and cervical cancer. Even after cessation of IL-2 administration, the transduced cell therapy of the present invention demonstrated improved lymphocyte survival and in vivo persistence, as well as enhanced tumor-killing ability, compared to untransduced cell therapies.
[0297] For example, for a patient with advanced (recurrent and metastatic) cervical cancer who has undergone radical resection and has participated in systemic radiotherapy, chemotherapy and targeted therapy, her ECOG score (an indicator of health status and tolerance to treatment) is 1 point.
[0298] The patient received the urethral cleansing program of the present invention and reinfused 5×10 9 After treatment with the TIL cell therapy method, in terms of safety, the subjects did not experience any safety events related to the therapy of the present invention, and all recovered after treatment; in terms of effectiveness, the metastatic lesions all achieved complete remission or partial remission.
[0299] A patient with advanced (recurrent and metastatic) neuroendocrine cervical cancer and invasive adenosquamous cell carcinoma had undergone multiple surgical resections, systemic chemoradiotherapy, and VEGF-targeted therapy. 9 Following treatment with genetically modified IL-15-expressing TIL cells, no safety events associated with the present invention were observed. As shown in Figure 28 , at month 4, target lesions were reduced by 69%, and brain lesions disappeared. This demonstrates the significant therapeutic efficacy of the present TIL cells against cervical cancer, including neuroendocrine cervical cancer.
[0300] The foregoing detailed description is provided by way of explanation and example and is not intended to limit the scope of the appended claims. Various changes to the embodiments of the present invention will be apparent to those skilled in the art and are intended to fall within the scope of the appended claims and their equivalents.
Claims
1. A composition comprising a TIL population in which at least a portion of cells have increased cytokine expression and / or enhanced activity, and a substance that reduces the number of lymphocytes and / or a substance that maintains the proliferation capacity of the TIL population.
2. The composition of claim 1, wherein the cytokine comprises an interleukin.
3. The composition according to any one of claims 1-2, wherein the cytokine comprises a cytokine having the ability to activate the STAT signaling pathway.
4. The composition according to any one of claims 1 to 3, wherein the cytokine comprises interleukin-15 (IL-15) and / or a functionally active fragment thereof.
5. The composition according to any one of claims 1-4, wherein the cytokine comprises membrane-anchored IL-15 and / or secreted IL-15.
6. The composition of any one of claims 1-5, wherein the cytokine comprises an IL-15 domain.
7. The composition according to claim 6, wherein the IL-15 domain comprises the amino acid sequence shown in SEQ ID NO:
2.
8. The composition according to any one of claims 1 to 7, wherein the cytokine comprises IL-15 receptor alpha (IL-15Ra) and / or a functionally active fragment thereof.
9. The composition of any one of claims 1-8, wherein the cytokine comprises an IL-15Ra extracellular domain.
10. The composition according to claim 9, wherein the IL-15Ra extracellular domain comprises the amino acid sequence shown in SEQ ID NO:
12.
11. The composition of any one of claims 9-10, wherein the IL-15 domain is directly or indirectly linked to the IL-15Ra extracellular domain.
12. The composition of claim 11, wherein the indirect connection comprises connection through a linker.
13. A composition according to claim 12, wherein the linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-9, (SEQ ID NO: 10) l, (alanine-proline) m, (glutamic acid-proline) n, (lysine-proline) p, and (SEQ ID NO: 11) q, and any combination thereof, wherein l, m, n, p and q are each independently an integer of at least 1.
14. The composition of any one of claims 1-13, wherein the cytokine comprises a transmembrane domain.
15. The composition of claim 14, wherein the transmembrane domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 13-18.
16. The composition of any one of claims 14-15, wherein the transmembrane domain is directly or indirectly linked to the IL-15Ra extracellular domain.
17. The composition of any one of claims 1-16, wherein the cytokine comprises an intracellular domain.
18. The composition of claim 17, wherein the intracellular domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 19-22.
19. The composition of any one of claims 17-18, wherein the intracellular domain is directly or indirectly connected to the transmembrane domain.
20. The composition of any one of claims 1-19, wherein the cytokine comprises a signal peptide domain.
21. The composition of claim 20, wherein the signal peptide domain comprises the amino acid sequence shown in SEQ ID NO:
1.
22. The composition of any one of claims 20-21, wherein the signal peptide domain is directly or indirectly linked to the IL-15 domain.
23. The composition of any one of claims 1-22, wherein the cytokine comprises the amino acid sequence shown in SEQ ID NO:
23.
24. The composition according to any one of claims 1 to 23, wherein the substance that reduces the number of lymphocytes comprises cyclophosphamide and / or fludarabine.
25. The composition of claim 24, wherein the cyclophosphamide is included in a dose of about 300 to about 500 mg / m2 / day.
26. The composition of any one of claims 24-25, wherein the fludarabine is included in a dose of about 20 to about 30 mg / m2 / day.
27. The composition according to any one of claims 1-26, wherein the substance that enables the TIL population to maintain its proliferation ability comprises interleukin-2 (IL-2) or a variant thereof.
28. The composition of claim 27, wherein the IL-2 is included in a dose of about 200,000 to about 600,000 IU / kg / time.
29. A kit comprising the composition of any one of claims 1-28.
30. Use of the composition according to any one of claims 1 to 28 and / or the kit according to claim 29 in the preparation of a medicament for treating a tumor.
31. A medicament for treating a tumor, comprising the composition according to any one of claims 1 to 28 and / or the kit according to claim 29.
32. A method for treating a tumor, comprising administering the composition of any one of claims 1 to 28 and / or the kit of claim 29 to a subject in need thereof.
33. The composition of any one of claims 1 to 28 and / or the kit of claim 29, for use in treating tumors.
34. The use according to claim 30, the medicament according to claim 31, the method according to claim 32, and / or the composition and / or kit for use according to claim 33, wherein the tumor comprises a solid tumor.
35. The use according to claim 30, the medicament according to claim 31, the method according to claim 32, and / or the composition and / or kit for use according to claim 33, wherein the tumor comprises one or more selected from the following group: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer and kidney cancer.
36. A method for treating tumors using a tumor infiltrating lymphocyte (TIL) population, the method comprising the following steps: (A) increasing the expression and / or enhancing the activity of cytokines in at least a portion of cells in a TIL population derived from tumor tissue to obtain a modified TIL population; and (B) administering a therapeutically effective amount of the modified TIL population to a subject suffering from the tumor.
37. The method of claim 36, wherein the cytokine comprises an interleukin.
38. The method of any one of claims 36-37, wherein the cytokine comprises a cytokine having the ability to activate a STAT signaling pathway.
39. The method according to any one of claims 36-38, wherein the cytokine comprises interleukin-15 (IL-15) and / or a functionally active fragment thereof.
40. The method of any one of claims 36-39, wherein the cytokine comprises membrane-anchored IL-15 and / or secreted IL-15.
41. The method of any one of claims 36-40, wherein the cytokine comprises an IL-15 domain.
42. The method of claim 41, wherein the IL-15 domain comprises the amino acid sequence shown in SEQ ID NO:
2.
43. The method of any one of claims 36-42, wherein the cytokine comprises IL-15 receptor alpha (IL-15Ra) and / or a functionally active fragment thereof.
44. The method of any one of claims 36-43, wherein the cytokine comprises an IL-15Ra extracellular domain.
45. The method of claim 44, wherein the IL-15Ra extracellular domain comprises the amino acid sequence shown in SEQ ID NO:
12.
46. The method of any one of claims 44-45, wherein the IL-15 domain is directly or indirectly linked to the IL-15Ra extracellular domain.
47. The method of claim 46, wherein the indirect connection comprises connection through a linker.
48. The method of claim 47, wherein the linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-9, (SEQ ID NO: 10) l, (alanine-proline) m, (glutamic acid-proline) n, (lysine-proline) p, and (SEQ ID NO: 11) q, and any combination thereof, wherein l, m, n, p, and q are each independently an integer of at least 1.
49. The method of any one of claims 36-48, wherein the cytokine comprises a transmembrane domain.
50. The method of claim 49, wherein the transmembrane domain comprises an amino acid sequence as shown in any one of SEQ ID NOs: 13-18.
51. The method of any one of claims 49-50, wherein the transmembrane domain is directly or indirectly linked to the IL-15Ra extracellular domain.
52. The method of any one of claims 36-51, wherein the cytokine comprises an intracellular domain.
53. The method of claim 52, wherein the intracellular domain comprises the amino acid sequence shown in any one of SEQ ID NOs: 19-22.
54. The method of any one of claims 52-53, wherein the intracellular domain is directly or indirectly linked to the transmembrane domain.
55. The method of any one of claims 36-54, wherein the cytokine comprises a signal peptide domain.
56. The method of claim 55, wherein the signal peptide domain comprises the amino acid sequence shown in SEQ ID NO:
1.
57. The method of any one of claims 55-56, wherein the signal peptide domain is directly or indirectly linked to the IL-15 domain.
58. The method of any one of claims 36-57, wherein the cytokine comprises the amino acid sequence shown in SEQ ID NO:
23.
59. The method according to any one of claims 36-58, wherein the increasing the expression and / or enhancing the activity of a cytokine in at least a portion of cells in a TIL population derived from a tumor tissue comprises introducing a nucleic acid encoding the cytokine into at least a portion of cells in a TIL population derived from a tumor tissue.
60. The method of claim 59, wherein the nucleic acid encoding the cytokine is integrated into the genome of the cell.
61. The method according to any one of claims 59-60, wherein the nucleic acid encoding the cytokine is introduced into the cell by electrotransduction.
62. The method according to any one of claims 59-61, wherein the nucleic acid encoding the cytokine is integrated into the cell genome via a viral vector.
63. The method of any one of claims 36-62, wherein increased expression of the cytokine comprises increased synthesis and / or secretion of the cytokine.
64. The method of any one of claims 36-63, wherein the proportion of cells expressing the cytokine in a TIL population derived from a tumor tissue in which the expression of the cytokine in at least a portion of cells in the TIL population is increased and / or the activity is enhanced is increased compared to a TIL population in which the expression and / or activity of the cytokine is not altered.
65. The method of any one of claims 36-64, wherein the proportion of cells expressing the cytokine in a TIL population derived from a tumor tissue having increased expression and / or enhanced activity of a cytokine in at least a portion of cells in the TIL population is increased by at least about 5% compared to a TIL population in which the expression and / or activity of the cytokine is not altered.
66. The method according to any one of claims 36-65, wherein in the TIL population derived from tumor tissue, the expression of cytokines in at least a portion of cells in the TIL population is increased and / or the activity is enhanced, and the proportion of cells expressing cytokines is at least about 5%.
67. The method of any one of claims 36-66, wherein the proportion of cells expressing cytokines in the modified TIL population used in a subject having the tumor is at least about 5%.
68. The method of any one of claims 36-67, further comprising reducing the number of lymphocytes in a subject having the tumor prior to administering the modified TIL population to the subject.
69. The method of any one of claims 36-68, further comprising administering cyclophosphamide and / or fludarabine to a subject having the tumor prior to administering the modified TIL population to the subject.
70. The method of any one of claims 36-69, further comprising administering cyclophosphamide and / or fludarabine to a subject having the tumor from day 4 to day 2 prior to administering the modified TIL population to the subject.
71. The method of any one of claims 69-70, wherein cyclophosphamide is administered to the subject at a dose of about 300 to about 500 mg / m2 / day.
72. The method of any one of claims 69-71, wherein cyclophosphamide is administered to the subject for 3 days.
73. The method of any one of claims 69-72, wherein fludarabine is administered to the subject at a dose of about 20 to about 30 mg / m2 / day.
74. The method of any one of claims 69-73, wherein fludarabine is administered to the subject for 3 days.
75. The method of any one of claims 36-74, further comprising: 9 or higher cell number to a subject having the tumor.
76. The method of any one of claims 36-75, further comprising administering the modified TIL population to a subject having the tumor by a one-time intravenous infusion.
77. The method of any one of claims 36-76, further comprising maintaining the proliferation capacity of the modified TIL population after administering the modified TIL population to a subject suffering from the tumor.
78. The method of any one of claims 36-77, further comprising administering interleukin-2 (IL-2) or a variant thereof to a subject having the tumor after administering the modified TIL population to the subject.
79. The method of any one of claims 36-78, wherein IL-2 is administered to the subject at a dose of about 200,000 to about 600,000 IU / kg / time.
80. The method of any one of claims 78-79, further comprising administering IL-2 to the subject for the first time 8 to 16 hours after the modified TIL population is used on the subject having the tumor.
81. The method of any one of claims 78-80, wherein after the first administration of IL-2 to the subject, IL-2 is administered to the subject once every 12 hours.
82. The method of any one of claims 78-81, wherein 24 hours after the first administration of IL-2 to the subject, the IL-2 is administered a second time according to the subject's tolerance.
83. The method of any one of claims 78-82, wherein IL-2 is administered to the subject 10 times or less.
84. The method according to any one of claims 36-83, further comprising: subjecting the TIL population derived from the tumor tissue to at least a first stage of in vitro expansion and a second stage of in vitro expansion, and in the second stage of in vitro expansion, co-culturing the TIL population with feeder cells.
85. The method of claim 84, wherein the first stage in vitro expansion is performed for at least about 7 days.
86. The method of any one of claims 84-85, wherein the second stage in vitro expansion is performed for at least about 7 days.
87. The method of any one of claims 84-86, wherein the TIL population is co-cultured with the feeder cells after contacting with the T cell activator and / or T cell growth factor for at least about 2 hours.
88. The method of any one of claims 84-87, wherein the feeder cells are irradiated peripheral blood mononuclear cells.
89. The method of any one of claims 84-88, wherein the feeder cells are added to the cell culture medium of the TIL population at a ratio of about 40:1 to about 400:1 of the feeder cells to the TIL population cells.
90. The method according to any one of claims 87-89, wherein the T cell activator comprises a CD3 antibody, a CD28 antibody, a CD80 antibody and / or a CD86 antibody, and an antigen-binding fragment of the above antibodies.
91. The method of any one of claims 87-90, wherein contacting the TIL population with the T cell activator comprises one or more methods selected from the following groups: (1) adding the T cell activator to the cell culture medium of the TIL population; (2) adding engineered cells expressing the T cell activator to the cell culture medium of the TIL population; and (3) adding a solid phase medium containing the T cell activator to the cell culture medium of the TIL population.
92. The method of any one of claims 87-91, wherein the initial concentration of each of the T cell activators in the cell culture medium of the TIL population is independently at least about 30 ng / mL.
93. The method according to any one of claims 91-92, wherein the amount of each of the T cell activators contained per mg of the solid phase medium is independently at least about 25 μg.
94. The method according to any one of claims 91-93, wherein the solid phase medium containing the T cell activator is added to the cell culture medium of the TIL population at a ratio of about 1:100 to about 1:2000 of the solid phase medium to the TIL population cells.
95. The method according to any one of claims 87-94, wherein the T cell growth factor is selected from one or more of the following groups: IL-2, IL-7, IL-12, IL-15, IL-21, gamma interferon, and functionally active fragments thereof.
96. The method of any one of claims 87-95, wherein contacting the TIL population with the T cell growth factor comprises adding the T cell growth factor to a cell culture medium of the TIL population.
97. The method of any one of claims 87-96, wherein the initial concentration of each of the T cell growth factors in the cell culture medium of the TIL population is independently at least about 300 IU / mL.
98. The method of any one of claims 36-97, wherein the tumor tissue-derived TIL population is selected from the following groups: a TIL population derived from fragments of tumor tissue, a TIL population derived from fragments of lymphatic metastases, a TIL population derived from pleural effusions, a TIL population derived from peritoneal effusions, a TIL population derived from tumor resection, a TIL population derived from biopsy, and a TIL population derived from resuscitation after cryopreservation.
99. The method of claim 98, wherein the fragments have a volume of about 1 cubic millimeter to about 27 cubic millimeters.
100. The method of any one of claims 36-99, wherein the tumor is a solid tumor.
101. The method of any one of claims 36-100, wherein the tumor is selected from one or more of the following groups: melanoma, ovarian cancer, cervical cancer, lung cancer, bladder cancer, breast cancer, head and neck cancer, pancreatic cancer, liver cancer, gastric cancer, colorectal cancer, and kidney cancer.
Citation Information
Patent Citations
Method of improving bile duct cancer by TIL immune cells
CN111195262A
Method for improving gastric cancer by TIL immune cells
CN111228472A
Method for clinically improving breast cancer by TIL
CN111840325A
Administration of tumor infiltrating lymphocytes with membrane bound interleukin 15 to treat cancer
US20220133801A1
